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p R E.F. A C E
One thousand year ago before the discovery of the 
circulation of the blood, and roughly thirteen centuries 
before it was known what happened in the intestine to ensure 
that organs were nourished by the process of digestive 
absorption, a verse in the Quran describes the source of the 
constituents of milk, in conformity with these notions.
To understand this verse, we have to know that chemical 
reactions occur in the intestine and that from there, 
substances extracted from food pass into the blood stream via 
a complex system, sometimes by way of the liver, depending on 
their chemical nature. The blood transports them to all the 
organs of the body, among which are the miIk-producing 
mammary glands. Basically there is the arrival of certain 
substances from the contents of the intestine into the 
vessels of the intestinal wall itself, and transportation of 
these substances by the blood stream (Dr Maurice Bucaille} 
(1,2).
This concept must be fully appreciated if we are to 
understand the verse 66, chapter 16 in the Quran:
" Verily, in the cattle there is a lesson for you. We
give you to drink of what inside their bodies, 
coming from a conjunction between the content of
the intestine and the blood, a milk pure and
pleasant for those who drink it. "
XX
S U M M A R Y
The idea behind this thesis developed during ray 
employment at the Department of Gastroenterology, Glasgow 
Royal Infirmary University NHS Trust, as a Clinical Research 
Fellow, The department is one of the very few that has been 
established over the years as a centre for gastrointestinal 
research and investigations.
The studies I performed aimed to take advantage of the 
availability of techniques for the measurement of protein 
synthesis using stable (i.e non-radioactive) labelling 
methods and mass spectrometric analysis to provide comparison 
of the rates of incorporation of labelled amino acids into 
mucosal protein sampled by gastrointestinal biopsy when 
presented intravenously and intragastrically.
This project concerns itself with the potential role of 
the tracer amino acid infusion techniques in the 
investigation of gastrointestinal diseases particularly those 
associated with mucosal atrophy and hypertrophy.
The introductory section reviewed the anatomical and 
functional properties of the small intestine and the 
manifestations of small intestinal dysfunction (Chapter 1).
The second chapter discusses protein synthesis and 
metabolism in general particularly the nitrogenous body 
composition, components of protein metabolism and the control 
of various stages of protein synthesis.
The contribution of the small intestine to the whole-body 
protein metabolism is referred to in chapter 3.
XXI
Chapter 4 discusses the development of stable isotope 
technology with reference to ^t's advantages which led to 
iit's jwide use in the field of metabolic investigation. I have 
also mentioned the radionuclide isotopes and the 
disadvantages of their use in man. Various applications of 
stable isotopes were summarised in this chapter. At the end 
of this chapter I have outlined the reasons for undertaking 
this work explaining the hypothesis behind it and the areas 
that I wished to test.
In section II (Chapter 5) I have summarized my objectives 
and set out the aims of the various studies included in this 
thesis.
In chapter 5 I have discussed the principles of the 
methodology of stable isotope applications including gas 
chromatography mass spectrometry and isotope ratio mass 
spectrometry. This was followed by a brief explanation of the 
methods I used to obtain intestinal mucosal samples and the 
way I handled these biopsies for various measurements 
(Chapter 7).
Chapter 8 concerns itself with the development of a 
technique for the measurement of protein synthesis utilizing 
the tracer amino acid incorporation principle. The choice of 
amino acid tracer and of tracer delivery technique is 
discussed in this chapter.
The experimental design, recruitment of subjects and 
patients and laboratory work are discussed in chapter 9. 
I have explained the type of statistical analysis and the
XXII
methods I used to calculate the rates of protein synthesis 
and whole-body protein turnover at the end of this chapter.
Section IV concerns itself with the development of a new 
method of measurement of gastrointestinal mucosal protein 
synthesis. I have discussed the use of tracer amino acid 
delivered by primed-constant infusion to define the source of 
the precursor for protein synthesis and it's rate of 
incorporation when supplied by luminal (intragastric) and 
basolateral (intravenous) route in normal subject (Chapter 
10) . The time course of labelled amino acids incorporation 
into the mucosal protein was assessed as well (Chapter 11).
Section V outlines the application of this newly 
developed method in patients with untreated coeliac disease. V
I delivered two amino acid labelled with ^^C via the p
intravenous (IV) and intragastric (IG) routes and measured 
the rates of protein synthesis, whole-body protein turnover V
■ias well as the protein and nucleic acids composition of the 
gut mucosa (Chapter 12). I have also measured the crypt cell 
histomorphometric characteristics and compared them with the v 
protein and nucleic acid composition of the mucosa. 
Correlation with vitamin 6^2 end folate status was assessed 
as well (Chapter 13).
'IPThe next application of the method described in this 
thesis was in patients with alcoholic liver disease as Idescribed in section VI (Chapter 14), I have measured the
protein synthetic capacity and the protein/DNA ratio as well #
-as the rates of intestinal mucosal protein synthesis and ;;|
XXIII
whole-body protein turnover in this group and attempted to 
correlate these rates with the indices of disease severity.
The last application of this method in this thesis was in 
a group of ileostomy subjects (Section VII, Chapter 15), I 
have chosen this group of patients, with ileostomy after 
having total colectomy for the treatment of ulcerative 
colitis, to give me a practical, timely access to the 
terminal ileum. The principal aim for this study was to 
measure the rates of mucosal protein synthesis in the small 
intestinal mucosa both proximally and distally.
In section VIII I have given an overall discussion of 
the results obtained from various studies beside the 
discussion in each study in it's relevant section where the 
results are interpreted, commented upon, and appropriate 
deduction drawn.
Considerations on future applications of this method of 
measuring gastrointestinal mucosal protein synthesis as well 
as the uses of stable isotopes are commented upon in section 
IX.
General assessment of the results and conclusions are 
given in section X followed by references, publications 
arising from this thesis and presentations at various learned 
societies.
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S E C  r I O N  I
1 N '1' R O D U C 'r I O N
CHAPTER 1
r \THE SMALL INTESTINE AND IT'S FUNCTIONS 
The gastrointestinal tract is a coordinated structure 
with the function of ingesting and absorbing nutrients and 
excreting unabsorbed and waste products. Knowledge of the 
small intestinal structure is important to understand the 
small intestinal mucosal functions, including protein 
synthesis and absorption, fully. The main anatomical and
physiological properties of the small intestine are presented V
tbelow.
1.1.1 STRUCTURE 
The small intestine is a convoluted tube comprising the
duodenum, jejunum and ileum extending from the pylorus to 
the ileocaecal valve where it joins the large intestine.A.During life ii^ 's average length is 5.92 m in women and 5.37 m 
in man and shortly after death becomes longer owing to the 
absence of muscle tone (3). On cross section it is consistent 
of mucosal layer, muscular layer and serosa (Figure 1.1.1).
The mucosal layer composed of many cells, the enterocytes, 
which have a relatively short life span and rapid turnover, 
being formed in the crypts and then migrating to the villus 
(Figure 1.1.2) (4,5).
1.1.2 FUNCTIONS
The small intestine has two principal functions; digestion 
and absorption (5,6).
Mesentery
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Figure 1.1.1 Schematic diagram of a cross section of the
small intestine.
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Figure 1.1.2 Schematic diagram of an enterocyte.
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1.1.2.A DIGESTION:
The basic process of digestion is hydrolysis. Diet is
mainly composed of carbohydrates, fats, proteins, vitamins, 
minerals and trace elements (7,8).
1.1.2.A.1 CARBOHYDRATES 
The carbohydrates which are in the form of
polysaccharides (starch) and disaccharides (sucrose, lactose 
& maltose) are digested into their monosaccharides (glucose, 
galactose & fructose). This process starts in the mouth where 
ptyalin is secreted in the saliva then hydrochloric acid 
(HCl) in the stomach provides some hydrolysis. However the
major share of hydrolysis occurs in the small intestine under 
the influence of pancreatic amylase. Finally the 
disaccharidases, maltase, sucrase & lactase, of the brush 
border of the intestinal villus epithelium split the 
disaccharides into their corresponding monosaccharides which 
are absorbed into the portal blood.
1.1.2.A.2 FATS
Fats of the diet composed mainly of triglycerides which 
are neutral fats. Each molecule consist of glycerol and three 
fatty acids. There are small quantities of phospholipids,
cholesterol and cholesterol esters. Very minute amount of fat I 
can be digested in the stomach by the gastric lipase. Between 1:%
95 to 99 per cent of all fat digestion occurs in the small
intestine under the influence of pancreatic lipase. The first 
step in fat digestion is émulsification, breaking the fat
:■
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globules into small size, which is achieved under the 
influence of bile salts that are secreted in the bile by the 
liver. The fat is split into monoglycerides and fatty acids. 
The intestinal epithelium contains a small quantity of lipase 
called enteric lipase which probably causes a very slight 
additional amount of fat digestion.
1.1.2.A.3 PROTEINS
Protein digestion begins in the stomach with the action of 
pepsin. The stomach contributes to only 10 to 20 per cent of 
total protein digestion. Most ingested protein is hydrolyzed 
in the duodenum and upper jejunum by the pancreatic enzymes 
trypsin, chymotrypsin and carboxy polypeptidases. The final 
product of this digestion is mainly small polypeptides plus a 
few amino acids. Oligopeptidases of the intestinal brush 
border hydrolyse di, tri and tetrapeptides. Although peptides 
consisting primarily of glycine, proline, hydroxyproline or 
dicarboxylic amino acids, they may be absorbed in peptide 
form, after which hydrolysis may occur within the mucosal 
cell. About 98 per cent of the protein finally becomes amino 
acids and the remaining 2 per cent is excreted in the faeces.
1.1.2.B ABSORPTION:
The small intestine plays the major role in absorption 
which occurs through the intestinal cells in various ways 
depending on the nutrient concerned. The stomach is a poor 
absorptive organ, only a few highly lipid soluble substances 
are absorbed in small quantities such as alcohol and some
7drugs. The total amount of fluids entering the small bowel is 
about 8 - 9 1 ,  most of it is absorbed leaving 1.5 1 to pass 
through the ileocaecal valve. The colon absorbs most of this 
fluid leaving only 50 - 200 mis to be excreted in the stool.
1.1.2.B.1 THE ABSORPTIVE AREA
The small intestinal mucosa is shaped in the form of folds 
called valvulae conniventes which increase the surface area 
of the mucosa by about three-fold. Millions of villi 
projecting from the intestinal mucosa for about 1 mm 
increasing the absorptive surface area by another ten-fold. 
The mucosal epithelial cells are characterized by a brush 
border consisting of microvilli. There is about 600 
microvilli from each cell. These microvilli increase the 
absorptive surface area by another 20-fold. Therefore the 
small intestinal mucosal absorptive area is increased by 
about 600-fold to a total of about 250 square meters (9).
1.1.2.B.2 MECHANISMS OF ABSORPTION
Absorption through the gastrointestinal mucosa occurs by 
active transport and by diffusion. Active transport provides 
energy to move a substance across a membrane against a 
concentration gradient or against an electrical potential. 
Diffusion means transport of substance through a membrane 
along an electrochemical gradient (10,11), The absorption of 
water, electrolytes and various nutrients is illustrated in 
(Figure 1.1.3) .
FOOD AMD DRINK
\ /
Salivary
am ylase
MOUTH
ESOPHAGUS
G astric  ju ice  
•pepsin  
•HCl
P ancrea tic  ju ice  
•b ica rbon a te  ■ 
•enzym es
In tes tin a l brush 
b o rd e r enzym es
STOMACH
DUODENUM
6—
a lcoho l
c i - .so /
iron'
ca lc ium  - 
m agnesium
JEJUNUM
glucose , ga lactose, fructose-
ILEUM
COLON
vitam in  C 
th ia m in  
r ib o fla v in  
¥- p y rid o x in e  
fo lic  acid  
protein
vitam ins A. D. E. K 
fa t
cho le s te ro l
b ile  salts and 
v itam in
N a ;K ' •
v ita m in  K fo rm ed by 
ba c te ria l ac tio n
H ,0
w a te r solub le 
v itam ins
RECTUM
ANUS
FECES
Figure 1.1.3 Gastrointestinal secretions and absorption
11..•1*
:
1-:yt
I
I9
Ï
-9
■Ï;;
if
■|
■1
:f
1.1.2.B .3 WATER AND ELECTROLYTES
Water is transported across the intestinal membrane by 
diffusion which obeys the osmosis laws. As ions and nutrients 
are absorbed, an isosmotic equivalent of water is also 
absorbed. Electrolytes such as sodium, iron, potassium, 
magnesium, phosphate and other ions are actively absorbed. 
Chloride ions are transported in most parts of the small 
intestine along with the positively charged sodium ions. In 
the distal ileum and in the colon there is active transport 
of chloride ions as well.
1.1.2.B.4 CARBOHYDRATES
Carbohydrates are absorbed actively in the form of 
monosaccharides across the intestinal membrane together with 
the sodium ions. The energy required is provided by the 
sodium transport system; the so called sodium co-transport 
theory.
1.1.2.B.5 FATS
Fat digestion end products, free fatty acids and mono­
glycerides, become dissolved in the lipid portion of the bile 
acid micelles which are soluble in the chyme. Once these 
micelles are in contact with the surfaces of the intestinal 
epithelial cells, both fatty acids and monoglycerides 
immediately diffuse through the epithelial membrane leaving 
the bile acid micelles still in the chyme. After entering the 
epithelial cells these fatty acids and monoglycerides are 
taken up by the smooth endoplasmic reticulum and recombined
10
to form new tri-glycerides which aggregate into globules 
along with absorbed cholesterol, phospholipids and small 
amounts of synthesized cholesterol. These globules then are 
excreted to the spaces between the cells by exocytosis; from 
there they pass into the lymph and now called chylomicrons.
1.1.2.B.6 PROTEINS
Protein absorption is an active sodium co-transport 
system which is similar to the glucose transport mechanism. 
Dietary protein assimilation is preceded by acid dénaturation 
in the stomach which renders the stable protein structure 
susceptible to hydrolysis, then luminal digestion producing 
small peptides and free amino acids (12), Protein absorption 
occurs mainly in the proximal jejunum (13). Most peptides and 
amino acids bind with a specific transport protein. There are 
many different types of these proteins in the intestinal 
epithelium. Amino acids enter the intestinal cell from the 
luminal side of the cell towards the basolateral side (6,10).
1.1.3 AMINO ACIDS TRANSPORT
Movement of amino acids into and out of cells is mediated 
by plasma membrane-bound activity which is an integral part 
of the small intestinal mucosal cells (14). Amino acids in
digestion and luminal absorption as well as a result of
the blood come from the products of enteral peptides
protein and amino acid metabolism in organs throughout the 
body (15).
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Free amino acids are transported across mucosal membranes 
via Na^-independent (facilitated transport) and Na^-dependent 
(secondary active transport) systems with only a small 
portion through unsaturable mechanism or diffusion 
(16,17,18,19), The definition of these systems is complicated 
by the presence of multiple transport systems within each 
group (20). Small intestinal amino acid transporters play a 
major role in whole body nitrogen metabolism during both 
absorptive and post absorptive states (14). In the absorptive 
state, enterocyte's apical and basolateral membranes transfer 
sodium and/or amino acids from the lumen to the portal blood 
in a way that sodium and water net absorption can be 
energetically coupled to amino acid uptake (21,22). Several 
of the apical (luminal) transport systems are different from 
those found on the basolateral membranes and are unique to 
absorptive epithelia. All the basolateral membrane systems 
are found else where in the body (15,23). In the post 
absorptive state circulating solutes are transported through 
the intestinal basolateral membranes into and out of 
enterocytes participating in splanchnic intermediary 
metabolism reaction (15). Some of the transport systems in 
the intestinal mucosa serve particular amino acids such as 
aspartate and glutamate (24), proline (25,26), neutral and 
cationic amino acids (26,27), neutral amino acids only 
(18,25). A recent study (28) shows that sodium dependent 
phenylalanine transport occurs only via a specific system Iscalled system B rather than a selective system previously 
designated PHE (29).
Î
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1.1,4 DYSFUNCTION
Small intestinal dysfunction may result in maldigestion; 
impaired nutrients hydrolysis and malabsorption; defective 
mucosal absorption of nutrients. In clinical practice 
malabsorption is used as a global term to include both 
aspects of dysfunction (30) .
1.1.4.A MECHANISMS AND CAUSES
1.1.4.A.1 MALDIGESTION
Maldigestion is due to digestive enzymes deficiency 
(pancreatitis, pancreatic carcinoma, parenchymal liver 
disease, cholestatic jaundice), inactivation (Zollinger- 
Ellison syndrome, bacterial overgrowth, drug effects) or 
rapid transit as in post-gastric surgery.
1.1-4.A,2 MALABSORPTION
In malabsorption there is a damage to the actual 
absorptive process itself which may follow damages to the 
small intestinal mucosa such as in coeliac disease, tropical 
sprue, Crohn's disease, radiation damage, ischemia, 
infections, infiltration, AIDS and Whipple's disease,
1.1.4.B CLINICAL PICTURE
The degree of impairment of absorption has to be profound 
before clinically significant malabsorption will occur (12) . 
The main symptom of malabsorption is diarrhoea which can be 
watery. The stool is bulky, pale and offensive. It tends to 
float and is difficult to flush owing to the increased gas
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content rather than fat (31). Weight loss is a common 
manifestation of malabsorption and in children there is 
growth retardation and failure of sexual development. 
Widespread nutrients deficiencies may result in various 
symptoms and signs (Table 1.1.1) (30).
1.1.4.C INVESTIGATIONS
Investigations should be undertaken;
a. to confirm the diagnosis,
b. to asses the severity and the extent of malabsorption and
c. to identify the underlying cause.
The intestine is more difficult to investigate as compared 
to other organs such as liver, kidney and heart. There are no 
simple tests which reflect intestinal function and integrity 
in the same way as liver function tests, urea and
function tests have been developed.
parenteral nutrition (TPN) the absorptive capacity of the 
intestine is severely compromised (32), accompanied by 
gradual intestinal atrophy (33). On the other hand, enteral
I
electrolytes or cardiac enzymes. Therefore many indirect
1.1.5 EFFECT OF FEEDING ON ABSORPTION
In the absence of luminal feeding, as in the case of total
feeding, particularly of amino acids or proteins promotes the 
morphological, digestive and absorptive integrity of the 
mucosa (34), therefore this route for nutrition should be 
chosen whenever possible.
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TABLE 1.1.1 Clinical manifestations of malabsorption.
MALABSORBED NUTRIENT SYMPTOMS AND SIGNS
Fat
Protein
Carbohydrate
Iron
Folic acid 
Vitamin B^2
Vitamin A 
Vitamin D
Vitamin K 
Calcium 
Magnesium 
Zinc
Bile salts
Fatty stool, watery diarrhoea, 
weight loss
Weight loss, muscle wasting, oedema, 
leuconychia.
Watery diarrhoea, flatus, abdominal 
distention, borborygrai.
Anaemia, glossitis, koilonycia, 
aphi^us dicers.
Anaemia, glossitis, aphthus ulcers. 
Anaemia, glossitis, neurologic 
di sorders.
Hyperkeratosis, night blindness. 
Rickets, osteomalacia, proximal 
myopathy,
Bruising, bleeding.
Parasthesia, tetany.
Parasthesia, tetany.
Acrodermatitis, poor wound healing, 
poor taste.
Watery diarrhoea
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CHAPTER 2 
PROTEIN SYNTHESIS AND METABOLISM
Protein and amino acids metabolism encompasses protein 
turnover, amino acids oxidation and overlap with carbohydrate
and fat metabolism (35,36).
1.2.1 PROTEIN TURNOVER
Turnover in general term means the process of renewal or 
replacement of a given substance. This process may either 
involve the production of newly formed material with the 
disappearance of some material already present or it may 
represent the exchange of material between two or more 
compartments (37). The protein turnover means the synthesis 
and breakdown of protein i.e protein exchange with a pool of
I
amino acids (35,37). The term breakdown should be restricted
to the degradation of protein into amino acids and the word 
catabolism is best avoided as it suggests an oxidative 
process. Thus the catabolism of amino acids to urea must be
distinguished from the breakdown of protein to amino acids
,3„.
1.2.2 BODY COMPOSITION
Quantitative knowledge of the amount of protein and amino 
acids in the body or an organ at a given time is difficult to 
obtain. Most of the methods for measuring the protein 
concentration and composition of the tissue in living 
subjects are indirect and based on assumption (38). Methods
I
:
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based on tissue biopsy are valuable and access to various 
tissues is nowadays possible. Among the tissues which have 
been sampled for such studies are gut and liver (39), breast 
(40), bone (41), skin and muscle (42), Although protein can 
be used as a fuel if they are not needed for protein 
synthesis (43), as in the case of carbohydrate and fat, it is 
mainly involved in the structure and function of cell (35). 
Surplus amino acids can not be stored nor are they excreted, 
rather used as fuel (43).
1,2.3 COMPONENTS OF PROTEIN METABOLISM
The dynamic nature of protein metabolism has been 
recognized for many years (44,37). Figure 1.2.1 shows the 
estimates of various components of protein metabolism. The 
rates of interchange of amino acids between various 
components were difficult to measure, therefore many workers 
depended on nitrogen balance to study these components of 
protein metabolism. They calculated the net difference 
between protein intake expressed as nitrogen content and 
nitrogen content of the body waste. These methods can give 
incorrect results if used less than obsessively and jit's) use 
in free-living human being is limited (45). With the 
development of stable isotope technology, accurate 
measurements of the rate of protein turnover and amino acid 
interchange between various compartments becoming possible 
and increasingly easier (46).
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Dietary 
intake 
100 g/d
Mucosal Cells Tissue
and digestive protein
juices 70 g/d pool
Protein synthesis
and breakdown
300 g/d
Skin
losses
Amino acids Free 2 g/d
absorbed amino acid
160 g/d pool
Faecal
loss
10 g/d Oxidative losses
Urea/ammonia 
in urine 88 g/d
Figure 1,2.1 The components of protein metabolism.
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1.2.4 THE AMINO ACIDS
Amino acids are organic compounds containing both an
amino group and a carboxyl group as expressed in the 
following formula;
RCH (NHg) COOH
alpha-amino acids are occurring in protein while in nature we 
have beta and gamma as well. The core of an alpha-amino acid 
is the carbon atom next to carboxylic group.
M-C-
■alpha-carbon atom
There are two optical isomers of amino acids in natural 
proteins L and D. All amino acids are asymmetric with the 
exception of glycine. There are four different groups 
attached to alpha-carbon atom; hydrogen atom, carboxyl group, 
amino group and R group and these groups are mirror images of 
one another and rotate polarized light in different 
directions (47).
1,2.4.A CLASSIFICATION
The principal constituents of proteins are amino acids, 20 
of which are present in the body and are physiologically 
important (Table 1,2.1), Many of these amino acids are 
compounds absorbed by the intestine from dietary protein
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TABLE 1.2.1 Concentrations of amino acids in plasma and RBC
AMINO ACID SYMBOL PLASMA * RED BLOOD CELLS**
ESSENTIAL
Histidine His 87 ± 3 120 ± 18
Isoleucine H e 63 ± 3 71 ± 3
Leucine Leu 120 ± 5 137 ± 6
Lysine Lys 195 + 9 177 ± 5
Methionine Met 25 + 1 20 ± 3
Phenylalanine Phe 53 + 2 62 ± 2
Threonine Thr 128 ± 5 157 ± 6
Arginine Arg 86 ± 3 258 ± 23
Valine Val 220 ± 8 248 ± 9
Tryptophan Trp 43 ± 2 13 ± 1
NON-ESSENTIAL
Alanine Ala 316 ± 17 419 ± 16
Asparagine Asn 47 ± 2 156 ± 4
Glutamate Glu — 446 ± 85
Glutamine Gin 655 ± 17 758 ± 15
Glycine Gly 248 ± 13 544 ± 21
Tyrosine Tyr 60 ± 4 82 ± 5
Serine Ser 114 ± 4 211 ± 6
Ornithine Orn 6 6 ± 4 271 ± 18
Taurine Tur 49 ± 3 157 ± 28
Citruline Ctr 34 ± 1 48 ± 2
Î
.1
* nmol/1 ± SE, plasma water
** umol/1 ± SE, intracellular water 
Source; M Rennie (35)
■
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digestion. Generally speaking these amino acids are divided 
into two main classes essential (dispensable) and non- 
essential (non-dispensable) amino acids (46,48). The 
essential amino acids could not be synthesized within the 
body in sufficient amounts to supply the demand of protein 
and nucleic acid synthesis (35). Strictly speaking the 
essential amino acids are isoleucine, leucine, lysine, 
methionine, phenylalanine, threonine, tryptophan, valine, and 
histidine; in infants (35,48) and arginine; during growth 
(48) . Arginine is synthesized by mammalian tissue but the 
rate is not sufficient to meet the needs during growth. In 
addition, if phenylalanine and methionine are present in only 
small amounts then tyrosine and cysteine may become rate-
limiting to growth or function as methionine is required in 
large amount to produce cysteine and phenylalanine is 
required in large amount to produce tyrosine (35,48), The 
whole concept of essentiality has become much less rigid
nowadays and the concept of "conditional essentiality" of 
certain amino acids was developed to take account of the fact
that, despite the ability of the body to synthesize them,
they are often required in amounts greater than the body's 
capacity to do so e.g glutamine, under conditions of disease 
(49,50) and injury and glycine in children treated for 
malnutrition (51).
1.2.4.B ANALYSIS
The introduction of automated amino acid analyzer made it 
possible to measure the concentration of various amino acids
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in various tissues (Table 1.2.1). Individual amino acids may 
be analysed by a variety of enzymatic methods (52). There is 
a wide range of methods based on chromatographic separation 
(35), and more recently tracer methods both radioactive and 
stable isotope have been used successfully (46). Over 90% of
'::ÿ
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the amino acids in the body are present in protein. The free 
amino acid pool contributes only a few percent to the total 
of amino acids in the body (53). The composition of the free 
amino acid pool in the plasma and within the intracellular 
compartment is the result of a variety of processes; amino 
acid synthesis, catabolism, transamination, protein 
synthesis, protein breakdown and amino acid transport. The 
complexity of amino acid metabolism prevents any attempt to 
partition the overall control of the free pool size between 
transport, intermediary metabolism and protein turnover (35). 
Nevertheless, factors which stimulate protein synthesis or 
inhibit protein breakdown seem to produce the largest changes 
in the free amino acid pool. Starvation is a good example 
(37), in which inhibition of protein synthesis and 
acceleration of breakdown markedly expands the free amino 
acid pool, particularly those amino acids with the smallest 
contribution to the free pool and thus the biggest protein 
bound/free ratio (e.g branched-chain amino acids, aromatic 
amino acids, and methionone). As can be predicted, feeding 
(which promotes anabolism) shrinks the pool whereas diabetes 
(which is catabolic) expands it.
S,
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1.2.5 GENETIC CONTROL OP PROTEIN SYNTHESIS
Cells and tissues are able to regulate their protein mass, 
the content of specific protein and the production of export 
protein in part by changes in the rate of protein synthesis 
(37). Protein synthesis takes place in the cell cytoplasm and 
involves interactions between ribosomes, mRNA, tRNA, amino 
acids, ATP, GTP and various enzymes. Genes control 
reproduction and function of all cells including protein 
synthesis.
1.2.5.A STAGES OF PROTEIN SYNTHESIS 
Protein synthesis and regulation are considered in two
stages; transcription and translation,
1.2.5.A.1 TRANSCRIPTION 
The DNA controls the formation of RNA which in turn
controls the formation of a specific protein. DNA controls 
protein synthesis by means of " genetic code " which consists 
of successive triplets of bases, that is each group of three -f
successive bases is a code word. The two strands of a DNA 
split apart, exposing the purine and pyrimidine bases -b
'
.
projecting to the side of each strand. The purines are 
guanine and adenine and pyrimidines are thymine and cytosine.
The successive triplets eventually control the sequence of 
amino acid in a protein molecule during it's synthesis in the 
cell. The genetic code is transferred from the DNA in the / 
nucleus to the RNA. This process is called "transcription".
The RNA then diffuses from the nucleus through the nucleolar II
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pores into the cytoplasmic compartment where it controls 
protein synthesis (10).
1.2.5.A.2 RIBONUCLEIC AIDS
Almost all DNA is located in the nucleus of the cell and
yet most of the functions of the cell are carried out in the
cytoplasm. This is achieved through the intermediary of 
another type of nucleic acid, RNA, the formation of which is 
controlled by the DNA of the nucleus. There are three types 
of RNA ;
a-Messenger RNA (mRNA)
These molecules, also called the "codons", carry the 
genetic code from DNA to the cytoplasm controlling the
formation of the protein. They are made in the nucleus in the 
region known as the nucleoplasm and composed of several 
hundreds to several thousands of nucleotides in single
strands. There are different codons for the 20 common amino 
acids found in protein molecules, also, one codon represents 
the signal for the start of manufacturing a protein molecule 
and three codons represent the signal to stop manufacturing 
a protein molecule.
b-Transfer RNA (tRNA)
All tRNA have similar basic clover-leaf structure with two 
binding sites, containing only about 80 nucleotides and are 
relatively small molecules in comparison with mRNA. Their 
molecular weight is about 25.10^ daltons and they transfer
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the activated amino acid molecules to the ribosomes to be 
used in assembling the protein molecules. Each type of tRNA 
combines specifically with one of the 20 amino acids that are 
to be incorporated into proteins. The specific code in the 
tRNA that allows it to recognize a specific codon is again a 
triplet of nucleotide bases and is called anticodon.
C-Ribosomal RNA (rRNA)
These rRNA constitute 60% of the ribosomes and form the 
matrix upon which protein molecules are actually assembled.
The remainder of the ribosome is protein, containing about 75 
different proteins that are both structural proteins and 
enzymes needed in the synthesis of protein molecule. Their 
molecular weight is up to 24.10^ daltons and they are made in
,the nucleolus. The process of protein formation on the 
ribosomes is called "translation" (10,37).
: -iM
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1.2.5.A.3 TRANSLATION
This process is divided into three phases; 
faj Initiation, binding of the ribosome to the mRNA and 
preparation for the synthesis of the first peptide bond in 
the peptide chain.
(b) Elongation, movement of the ribosomes along the mRNA as 
it incorporates amino acids into the growing peptide chain.
(c) Termination, completion of synthesis with release of the 
newly synthesized peptide chain and of the ribosome from the 
mRNA.
iJ
 . _
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The successive amino acids in the protein chain combine 
together by peptide linkage according to the following 
chemical reaction:
|FH2^  o
R-C-C-OH + H-N-C~COOH = H2O + r\-C"N-C“COOH
In this reaction, a hydroxyl radical is removed from the COOH
portion of one amino acid, while a hydrogen of the NH2
portion of the other amino acid is removed. These combine to 
form water and the two reactive sites left on the two
successive amino acids bound with each other resulting in a 
single molecule.
For each peptide linkage formed during protein synthesis a 
very large amount of energy is consumed requiring breakdown 
of four molecules of ATP as shown in the following reaction:
aminoacyl-tRNA
amino acid + tRNA + ATP-------- >aminoacyl-tRNA + AMP + PPj_
synthetase
Thus protein synthesis is one of the most energy-consuming of 
all cell's functions (10,37).
i
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CHAPTER 3
CONTRIBUTION OF THE SMALL INTESTINE TO THE OVERALL PROTEIN
METABOLISM
1.3.1 INTRODUCTION
The contribution of various tissues to whole-body protein 
turnover remains unknown. Each tissue must contribute 
according to it's mass, the amounts and composition of it's 
proteins and their turnover rates (54). Although the liver 
has the largest mass of amino acid catabolizing enzymes and 
containing the enzymes of urea cycle, other tissues such as 
the intestine, muscles, adipose tissue and kidneys also 
participate substantially in the intermediary amino acid 
metabolism of the whole-body and therefore the overall 
nitrogen economy (35). Protein turnover in the intestinal 
mucosa has various components (55). In the gut mucosa cell 
function is different at different levels. The physiology of 
absorption is not the same in the jejunum and ileum, the 
rates of cell renewal are not the same, and it is likely that 
rates of protein synthesis and breakdown are not the same 
(37) . f
i'1.3.2 COMPONENTS OP INTESTINAL PROTEIN SYNTHESIS
Protein synthesis in the gut has three components which 
serve different functions;
1.3.2.A CELL RENEWAL
The first component of protein synthesis in the small 
intestine is the cell renewal. The life span of the iI
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Intestinal epithelial cells is short, so that cell renewal 
must make a large contribution to protein synthesis in the 
tissue. In man the crypt cells proliferate at the rate of 1- 
2% per h (56). The turnover times of intestinal epithelial 
cells in man ranging ifrom 3 days in the ileum to 5 to 6 days 
in the duodenum (4) . Thus the fractional renewal rate would 
be at least 20% per day. The weight of the intestinal tract 
is 5% of the body weight (57) and if half of this is 
epithelium then the total mass of cells renewed per day would 
be about 350 gm in an adult man. This very rough estimate was 
confirmed by measuring the DNA content of the exfoliated 
cells in the intestinal perfusate (58), By this method it was 
estimated that the total weight of epithelial cells lost from 
the human gut would be 287 gm per day. If the cells have a 
protein content of 20%, this would mean 50-60 gm protein 
synthesized per day in the production of new cells.
1.3.2.B EXPORT PROTEIN
The second component of protein synthesis in the 
intestinal tract is the production of secreted or export 
proteins. It has been estimated that in an adult man about 17 
gm protein is secreted per day through saliva, gastric juice, 
bile and pancreatic juice (57). In the crypts of the 
intestinal epithelium, the greater part of protein synthesis 
is for the production of new cells (59) whereas in the villi 
specific enzymes proteins are synthesized (55).
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1.3.2.C INTRACELLULAR TURNOVER
The third component of protein synthesis in the gut is 
intracellular turnover. However there does not seem to be any 
way of measuring it directly in man. The combination of 
protein cell turnover and export protein amount to about 70- 
80 gm protein per day which is about one quarter of total 
body turnover in man. It seems that the intestinal tract 
clearly makes an important contribution to overall protein 
synthesis, probably more important than that of liver (37).
1.3.3 SOURCE OF AMINO ACIDS
The amino acid taken up into the epithelial cells is 
derived from two sources; the blood stream and the lumen of 
the gut. From animal studies it seems that there is a 
preferential uptake from one or other route according to the 
anatomical location of the cells (15,60). After IV 
administration of a precursor amino acid protein from cells 
near the villus-crypt junction is most heavily labelled 
whereas after intraluminal administration of the precursor 
protein from cells near the villus tip is most heavily 
labelled. Even if the labelled amino acids were infused by 
both route it would not be possible to achieve the same 
specific activity of enrichment in blood and in gut contents. 
By giving a prime dose, to flood the system, it would be 
possible to overcome this problem as after the bolus 
injection all the amino acids pools reach more or less the 
same specific activity or enrichment. However if the infusion 
continued for more than 6 h there will be more chance of
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labelled protein to be broken down before the end of the 
incorporation period.
1.3.4 EFFECT OF NUTRITION
It seems that food intake stimulates protein synthesis and 
decreases protein breakdown in the fed state. In the fasted 
state, protein synthesis falls and protein breakdown rises. 
The swing between "gain" in fed state and "loss" in the 
fasted state is greatest when protein content of the diet is 
highest (35) . It has been found recently that total 
parenteral nutrition (TPN) appears to increase rate of 
protein synthesis in the human gastrointestinal tract (39).
The whole-body protein dynamics and it's response to 
nutrient supply is now better understood after the 
application of tracer amino acid infusion studies (35).
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CHAPTER 4
THE DEVELOPMENT AND POSSIBLE APPLICATIONS OF STABLE ISOTOPES
1.4.1 ISOTOPE TRACERS
Isotopes are atoms, (iso - same, topos = place; occupying 
the same place in the periodic table) (61), of different 
numbers of neutrons but the same number of protons i.e are 
members of the same element (46). Isotopes are used to label 
certain chemical compounds of interest to form a tracer. 
Tracer is a compound which is chemically identical to the 
compound of interest (the tracee), but distinct in some 
characteristic that enables it's precise detection. 
Therefore, isotope tracer is a tracer in which one or more 
naturally occurring atoms in specific position(s) substituted 
with an isotope of that atom with a less common abundance 
(46) .
The chemical properties of the atom is determined by the 
electronic configuration and not the number of neutrons. The 
specifically enriched atom is referred to by identification 
of the weight of the atom by a superscript prior to the
letter e.g and refer to carbon atoms of atomic
mass of 12, 13 and 14 respectively (^^C is the most abundant
mass, is the stable isotope and is the radioactive
isotope). The atomic mass number is the number of protons
plus neutrons in the atom and the mass differences of
isotopes are due to different numbers of nuclear neutrons. In 
our studies we used labelling of amino acids leucine and
valine, and are the most widely used isotopes in
metabolic studies (Table 1.4.1),
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TABLE 1.4.1 Carbon and nitrogen stable isotopes
ELEMENT STABLE ISOTOPE % OF NATURAL ABUNDANCE
C
N
12
13
14
15
98.89 
1 . 11
99 .63 
0 .37
The position within a molecule of an enriched carbon is 
referred to by the appropriate carbon number preceding the 
abbreviation of the description of the isotope used in the 
tracer, e.g l-^^C-leucine refers to a molecule of leucine in 
which position 1 is labelled with carbon enriched with the 
stable isotope mass 13 (46).
1.4.2 STABLE ISOTOPES
These are the isotopes in which the neutrons are stable 
with no evidence of spontaneous degradation i.e they do not 
transmit into another element. The use of these isotopes as a \/
metabolic tracer predates the use of radioactive isotopes by 
nearly 20 years (62,63), however, the analysis was by 
cumbersome techniques. It was probably the difficulty of 
this analysis that hindered the more widespread use of the 
stable isotopes (35). With the advent of scintillation
/
3 2
counting and the availability of a wide variety of 
radioactive tracers, most kinetic studies in the 1950s and 
1960s used radioactive tracers (46) . Over the past 15-20 
years the use of stable isotopes have become increasingly 
popular, especially since the development of mass 
spectrometers interfaced with gas chromatography (35,46). 
Greater availability of stable isotopes as well as the 
increased awareness of the health hazards of radioactivity, 
also stimulated the use of stable isotopes (46).
1.4.2.A BIOLOGICAL ADVANTAGES:
The most obvious advantage of stable isotopes is that they 
are not radioactive and present little or no risk to human 
subjects (46). Side effects in vivo are not expected from 
administration of "tracer" doses of carbon 13 since carbon 
13, naturally contributes to 1.11% of the carbon pool (Table
1.4.1), has not been found to demonstrate more than trivial 
in vitro isotope effects on chemical reaction with carbon 13- 
labelled substrate (64) . ^^C and ^^N can be shown to affect
certain parameters of cell function at extremely high levels
of enrichment that would never be attained in an in vivo 
study in humans (65). There is no evidence that stable 
isotopes tracers present an identifiable risk to human
subjects at the highest levels of enrichment that might 
reasonably be achieved. The use of label tracer requires the 
assumption that the labelled molecule will not be
discriminated from the unlabelled molecules and that the 
labelled molecule will trace the movement of the unlabelled
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molecules. Furthermore, there is little evidence that 
enzymatic effects are of concern in in vivo studies when the 
tracer atom is not directly involved in a metabolic reaction 
(46) .
1.4.2.B ANALYTICAL ADVANTAGES:
In addition to the safety of stable isotopes for human use 
in metabolic investigations, there are other advantages of 
stable isotopes (66). Most obviously, the availability of 
stable isotopes for nitrogen and oxygen (l^N and 1^0) whereas 
there are no practical radioactive isotopes for these two 
elements. When analysis by gas chromatography mass 
spectrometry is used, it is often possible to determine 
enrichment on small samples of blood. There are possibilities 
of; adding an internal standard and thereby measuring the 
concentration and enrichment spontaneously; selective ion 
monitoring generally enables reliable documentation of the 
purity of a sample being analysed; simultaneous and repeated 
use of several tracers is possible in the same subject, since 
the process of mass spectrometry isolates individual 
compounds before analysis. Thus several amino acids enriched 
with can be given simultaneously and the enrichment of
each tracer measured independently of the other labelled 
compounds; and it is frequently possible to determine the 
enrichment in specific position of a molecule.
In some of our studies we used two tracers simultaneously 
i.e and ^^C-valine in the same subjects to
I
34
determine the effect of route of delivery on the protein 
synthesis in normal subjects and in coeliac patients.
1.4.3 RADIOACTIVE ISOTOPES
Radioactivity means the spontaneous rearrangement of 
protons and/or neutrons in an unstable atomic nucleus in such 
a way that expandable energy becomes available. A proton may 
change into a neutron or vice versa, or an orbital electron 
may be captured by the nucleus, thus altering the nuclear 
charge (transmutation); alpha-particles, electrons, or
positrons may be shot out at high speed; or the excess energy 
may be carried away by garama-photons or conversion electrons.
leaving proton and neutron numbers unchanged (isometric
transition). There are characteristic decay processes and
omitted radiations for each radionuclide. Radioactive
■isotopes are the isotopes in which neutrons spontaneously Idegrade to form an electron and a proton. Radioactive tracers of amino acids have been used successfully in tracing 
plasma amino acid turnover (35). Radioactive is an incorrect 
term and is better called radionuclide (61) which is a 
nuclide that spontaneously exhibits radioactive decay. 
Determination of B radioactivity in a sample is done by 
scintillation counting. The technique allows simultaneous 
counting of and Account must be taken of quenching of
counts to convert from count per minute (observed by the 
instrument) to disintegrations per minute (46).
Most kinetic studies in the 1950s and 1960s used 
radioactive tracers prior to the advent of sensitive and
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user-friendly mass spectrometers in various configurations 
(35) .
1.4.3.A BIOLOGICAL DISADVANTAGES:
Administration of radioactive tracers involves health risk 
to the subjects. Therefore the dose of radioactivity must be 
calculated and compared with commonly encountered radiation 
exposures to gauge risk. Table 1.4.2 shows the significant 
risk to different systems after exposure to various doses of 
irradiation (67).
In many European countries, the use of radioactive tracers 
in normal, healthy subjects is severely limited by law; and 
even in those countries where the law restrictions are less
severe, ethics committees and regulatory authorities rightly
demand a very good case to be made for the use of radioactive
tracer in adults of reproductive age (68), and it is
impossible to study children (37).
1.4.3.B ANALYTICAL DISADVANTAGES:
The accuracy and precision with which metabolism can be 
traced using radioactive amino acids is usually less than 
with stable isotopes amino acids, because measuring the 
extent of labelling with radioactive amino acids involves two 
separate processes, i.e measurement of the rate of 
disintegration of radioactive isotope and the chemical 
concentrations of the tracer plus tracee. With stable isotope 
measurement methods, the quantity analogous to the specific
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radioactivity is the isotope ratio and this can be obtained 
in a single measurement by a mass spectrometer. Liquid 
scintillation counters can be relatively inefficient way 
of measuring radioactivity; and this means that to obtain 
reliable measurements of incorporation of a label into a 
protein, a high dose of labelled amino acid would need to be 
used (69,70), unless prolonged counting times for the samples 
are used as a means of ensuring high precision.
1.4.4 FUTURE PERSPECTIVE
previously associated with employing stable isotope tracers
The practical applications of these isotopes include the 
study of body composition, energy balance, inter-organ 
transport and oxidation of the three major metabolic fuels
i
In the last 15-20 years, the developmental problems
for the metabolic investigations In vivo have largely 
disappeared. Furthermore, the use of stable isotopically 
labelled material became widely available and less expensive.
I
i
i.e glucose, fat and amino acids, the pathophysiology of
metabolic events in growing children (66) and in disease 
conditions and in all branches of medical research. Table 
1.4,3 shows the range of stable isotope applications in 
clinical research without attempting to be comprehensive.
'i
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TABLE 1.4.2 Risks related to radiation dosages.
EXPOSURE (RADS) SYSTEM SIGNIFICANCE
10
10
20
100 single 
dose
6 50 single 
dose
Bone marrow
Sensitive organ
Whole-body
Reproductive
system
Whole-body
Whole-body
Risk of leukemia 
1/50 000
Risk of cancer 
1/50 000
Increased number of 
chromosome aberration 
in peripheral blood, 
no detectable sign 
or symptom.
doubling spontaneous 
mutation.
Mild irradiation 
sickness
LD 50 Ï
i
■’S'
Î■fi"
LDgQ : lethal dose in 50% of exposed population
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TABLE 1.4.3 Clinical and research applications of stable 
isotopes.______________________________
I
%
APPLICATION TRACER
Energy expenditure (71)
Total body water (72)
Protein turnover 
Whole body (73)
(74)
Tissue & individual proteins (75,
76)
Fat oxidation and turnover (77,78)
Carbohydrate oxidation, turnover(79) 
Amino acid kinetics
Transamination (75,80,81)
Pool size, turnover (82)
Substrate cycling (83)
Trace elements and mineral 
metabolism (84,85,86)
Inborn errors of metabolism
Metabolic pathways elucidation(87 
Heterozygot detection (PKU) (88) 
Pharmacokinetics (89)
[13c]leucine,[^^N] 
glycine, [^^N]lysine 
( ) phenylalanine 
[ ] leucine, [^^N] 
glycine
[l^C]palmitate,
glycerol
^^C]glucose
[^^N,^^C]leucine 
[15n ]glycine, [^^N] 
alanine, [l^C]leucin 
[^Hg-fatty acids and 
glucose
43ca,  44ca^ 54pe^57p,%
204pbg 65c u , 702n, 28p[g
Various
phenylalanine 
Various
Ï
a
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TABLE 1.4.3 Clinical and research applications of stable 
isotopes, (continuation)_______________
APPLICATION TRACER
Breath tests
Lactase deficiency (90,91) 
Fat malabsorption (92,93,94)
Liver function (95,96,97)
Bacterial overgrowth (98) 
Helicobacter pylori (99) 
Gastric emptying (100,101,102)
Cancer, liver (103)
urinary bladder (104) 
therapy response (105)
Ileal dysfunction (106)
[^30]lactose 
[^3q]-tri-glycerides 
and fatty acids 
[^3q]aminopyridin,
[130]galactose
[130]giycholate 
[13c]urea
[13c]glycine / [l^C] 
octanoic acid 
[13c]galactose 
[13c]tryptophan 
deutrium labelled 
cytotoxic drugs.
[13c]-labelled
glycocholate
It seems likely that within the near future the stable
isotopes will totally 
quantitative metabolic 
(107) .
replace radioactive isotopes in 
studies involving human subjects
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1.4.5 GASTROINTESTINAL MUCOSAL PROTEIN SYNTHESIS
Animal work suggested that the gastrointestinal tract 
contributes significantly to the whole-body protein 
metabolism. There has been a substantial interest in the 
gastrointestinal protein metabolism in man.
So far there have been no reliable, safe, robust methods 
for the measurement of the incorporation of tracer labelled 
amino acids into protein in the gastrointestinal tract widely 
available although there have been reports of measurement of 
tracer incorporation into normal and diseased 
gastrointestinal tract tissues on an ad hoc basis.
The purpose of the present work was to develop a method 
which would allow measurement of protein synthesis in any 
gastrointestinal mucosal tissue capable of being sampled.
In designing such a method, two questions of some 
significance need to be addressed. The first question is 
whether a preferential route of entry of amino acids to the 
synthetic precursor machinery exists in small intestinal 
mucosal tissue. This is an important question the answer to 
which has implications for the preservation of the function 
of the gastrointestinal tract during enteral and parenteral 
feeding. The second question is whether the tracer amino acid 
is incorporated into gastrointestinal protein to an extent 
proportional to the time of exposure of the tissue to the 
tracer i.e linear incorporation. The answer to this question 
would validate the method of calculating the rate of protein 
synthesis as a fractional rate.
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Furthermore, since comparison will be made of the rates 
of protein synthesis in subjects without gastrointestinal 
disease and in others with, for example coeliac disease and 
alcoholic liver disease where the nutritional status is 
affected by the disease state, it will be possible to i ; |  
discover something about the likelihood that differential 
rates of protein synthesis are involved in pathological
-d':,
changes known to occur in the gastrointestinal mucosa in 
these conditions.
deranged function. Thus I have chosen normal subjects and
Since the investigation aims to discover new facts about 
normal physiology as well as it's derangement in pathological
■circumstances I would require to study patients with normal
■gastrointestinal tract function as well as others with
patients with untreated coeliac disease, alcoholic liver 
disease and subjects with ileostomy following total colectomy
"ifor the treatment of ulcerative colitis to give me access to
;the distal part of the small intestine.
These investigations aimed to take advantage of the 
availability of techniques for the measurement of protein 
synthesis using stable isotope labelling methods and mass
spectrometric analysis. I
33d:
"Si
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CHAPTER 5 
AIMS
The overall aim of the studies described in this thesis 
was to assess certain aspects of the small intestinal mucosal 
function in normal subjects and in certain disease 
conditions.
2.5.1 NORMAL SUBJECTS
The aims were;
1) to measure the gut mucosal protein synthesis,
2) to assess the protein, DNA and RNA composition of 
the intestinal mucosa,
3) to examine the effect of the route of amino acid 
delivery on the protein synthesis in the intestinal 
mucosa, and
4) to assess the pattern of amino acid incorporation 
into the mucosal protein in the small intestine.
2.5.2 COELIAC DISEASE PATIENTS 
The aims were;
1) to assess the effect of untreated coeliac disease on 
the small intestinal mucosal protein synthetic rate 
and capacity and on the whole-body protein turnover.
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2) to examine the effect of the route of amino acid
delivery on the protein synthesis in the intestinal
mucosa,
3) to compare the protein, DNA and RNA composition of
the intestinal mucosa with the histomorphometric
characteristics of the crypt cells in the intestinal 
mucosa, and
4) to investigate if vitamin B^2 folate status has
any association with the crypt cell morphometry.
2.5.3 ALCOHOLIC LIVER DISEASE PATIENTS 
The aims were;
1) to assess the effect of alcoholic liver disease on the
small intestinal mucosal protein synthetic rate and
capacity, and on the whole-body protein turnover,
2) to correlate the severity of alcoholic liver disease
with the changes in the rates of small intestinal 
mucosal protein synthesis and whole-body protein 
turnover, and
3) to assess if the amount of consumed alcohol has
an effect on the small intestinal mucosal protein 
synthesis and the whole-body protein turnover.
:f
■a*
i
£;Ï
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2.5.4 ILEOSTOMATES
The aims were;
1) to measure the rate of small intestinal mucosal 
protein synthesis in the proximal and the distal 
parts of the small intestinal mucosa in subjects 
with ileostomy,
2) to investigate if there is any variation in the rate 
of small intestinal mucosal protein synthesis between 
the various regions of the small intestine, and
3) to assess the effect of ileostomy on the whole-body 
protein turnover.
I
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M E T H O D O L O G Y  A N D  E X P E R I M E N T A L
D E S I G N
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CHAPTER 6 
STABLE ISOTOPES TECHNOLOGY
3.6.1 INTRODUCTION
The demonstration of the existence of isotopes of the 
element neon using mass spectrometry (MS) was first made by 
Sir J J Thompson in 1913 (107) , Today the basic principle 
used to analyze stable isotopes remains unchanged.
Ashton laid down the ground work of stable isotope tracer 
studies by using the measurement of isotope ratio by mass 
spectrometry to establish the basis of the whole number rule
of atomic weight in the 1930s (46). However, it was
Schoenheimer et al. (108) in the early 1930s who was able to 
demonstrate the dynamic nature of protein metabolism in the 
body using isotope ratio mass spectrometry (IRMS).
The chromatographic system using gas to carry molecules 
through a sorbent filled column was suggested by Martin and 
Synge in their Nobel Prize winning study published in 1941
(109). The introduction of gas-liquid chromatography in 1950s
(110) and it's subsequent interface with MS was a major 
breakthrough in analytical technology. The gas chromatography 
and mass spectrometry have proven to be well matched for
combined operation, and advances in gas chromatography-mass 
spectrometry (GCMS) methodology have been the main reason
research (35,46).
shown in figure 3.6.1
behind the wider application of stable isotopes in metabolic
#
A schematic representation of the components of GCMS is
■|«
É
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3.6.2 GAS CHROMATOGRAPHY
Chromatography is a method that separates mixtures of 
substances by their differential migration through a two- 
phase system consisting of a mobile phase (flowing gas or
liquid) and a stationary phase (fixed porous sorbent). The 
primary function of the mobile phase is to promote the
progression of analysts through the system and the primary 
function of the stationary phase is to imp^ Selectively the )< 
progress of different analysts. The mobile phase in GC is a 
flowing inert carrier gas and in liquid chromatography is a 
chemically active solvent.
Separation of volatile compounds by GC is simple, rapid and 
reproducible method of high resolution. The sample is
vapourised in the heated injector and swept through the 
column by an inert carrier gas such as helium, hydrogen, 
nitrogen or methane. The sample in the carrier gas is
/ Areferred to as the gas phase or mobile phase.^the separation 
process on the column occur in a temperature-controlled oven 
and effluent enters the MS interface.
3.6.2.A DERIVATIZATION
Most metabolic substrates in the body are not volatile, 
therefore to be separated by GC these compounds must be
converted to derivatives that are ; thermally stable,,.
chemically inert and volatile at temperature below about 
300^C. The strong intermolecular attractions between polar 
groups render most metabolic substrates non-volatile. 
Derivatization can markedly increase volatility by masking of
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polar groups. Replacement of hydrogen in these groups by 
alkylation, acylation or silylation increases the volatility. 
There are important factors to be considered in choosing a 
derivative to use for GCMS analysis such as ease of 
preparation, stability of the derivatized sample, the 
separation characteristic on the GC, the resulting 
fragmentation pattern as well as prior use and documentation 
of particular derivative. Account must be taken of the extra 
atoms added by the process of derivatization and their 
contribution to the observed mass spectrometry data.
3.6.2.B PARTITION COEFFICIENT (K)
The injection port of the gas chromatogram is about 250^C 
so that all compounds of the sample are vapourized. After 
injection the sample is partitioned between the inert carrier 
gas and a stationary phase which is a nonvolatile liquid 
coated onto the sides of the column or onto an inert, size- 
graded solid and packed into column. The different compounds 
in a sample will be present partially in the stationary phase 
and partially in the mobile phase depending on their vapour 
pressure. The ratio of the weight of solute per ml 
stationary phase (nonvolatile) to the weight of solute per ml 
mobile (gas) phase is the partition coefficient (K). A 
compound with a low K (high vapour pressure) will be present 
to a greater extent in the gas phase and come of the column 
(elute) more rapidly than will compounds with lower vapour 
pressure. The column temperature can be regulated to enable 
the elution of the compounds of interest in as short a period
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as possible. The GCMS interface can also be heated, so that 
the eluted compounds do not condense.
3.6.3 GC-MS INTERFACE
The carrier gas flow rate for a a GC is too high and at
too great a pressure to enter into the ion source of the MS.
The sample is also diluted with the carrier gas. Therefore a 
separator at the interface between GC and the MS is required 
to reduce the pressure and increase the relative amount of 
sample that enters the MS. The separator depends on the
difference between the physical properties of the carrier gas 
and the sample.
3.6.3.A TYPES
Mainly there are three types of separators commonly in use 
i.e jet, effusion and indirect membrane separators (Figure
3.6.2) .
(a) Jet Separator; The effluent from the GC passes
through a small orifice into an evacuated tube. Increased 
concentration of the sample gas is achieved by pumping the 
lighter carrier gas away from the heavier component i.e the 
sample in the jet stream. The sample continues into a 
collecting capillary that leads into the ionization chamber 
of the MS.
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VENTGC
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Membrane
MS
Figure 3.6.2 Schematic drawing of three separators used to
interface GC with MS.
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(b) Effusion Separator; The effluent from the GC passes 
through an inlet constrictor that reduces pressure from 
approximately 760 to 1 Torr. The carrier gas is separated 
from the sample because the rate at which the gas effuse
through the glass frit to the external vacuum is inversely 
proportional to the square root of the molecular weight and 
directly proportional to the partial pressure of each 
component. The concentrated stream then passes to the
ionizing chamber through a second restrictor and the carrier 
gas will preferentially effuse through narrow passage in a 
porous glass frit and be pumped away by a forepump.
(c) Indirect Membrane Separator; The preferential passage 
of organic vapour through a silicone polymer membrane 
concentrates a sample when a membrane separator is used. The 
carrier gas is insoluble in the polymer and is therefore 
pumped out, while the vapour of sample can pass directly into 
the MS. This type of separator is temperature dependent and 
there is also a significant time lag between the entry of 
compounds and their transfer to the MS which made the
membrane separator less favoured than the other types of 
separators.
Some MS are designed so that the GC effluent enter in the 
ion source directly so that prior sample separation is not
required. This is particularly common when a capillary GC is 
used, since the carrier gas flow rate is so much less than 
when a packed-column GC is used.
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3.6.4 MASS SPECTROMETRY
The basic principle of mass spectrometry is that the 
sample is introduced into a vacuum chamber through the inlet 
and then ionized and advanced through the mass filter or 
analyser. The ions are sorted by their mass-to-charge (m/e) 
ratios. After mass analysis, the separated groups of ions are 
collected and a data system converts the signals from the 
ions to the desired output. The processes within the MS all 
occur when under high vacuum conditions.
3.6 .4.A IONIZATION CHAMBER
For the analysis of isotopic enrichment, two types of 
ionization are most widely used, electron impact and chemical 
ionization.
Electron Impact, Sample molecules enter the 
ionization chamber where they pass through a beam of 
electrons. This beam is emitted from a heated filament and is 
attracted toward a positively charged plate. If a molecule is 
struck by an electron sufficient energy may be imparted to 
remove an electron from the sample molecule resulting in a 
molecular ion:
M + e = M”^ + 2 e .
The electron trap is held at a potential that is positive 
with respect to the filament and it is conventional to set 
the electron beam energy at 70 eV. The energy in excess of 
that need to ionize the sample is dissipated by fragmentation 
of the molecular ion. The pattern of fragmentation, as
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reflected by the MS, of a sample is consistently 
characteristic of that particular sample. This ionization 
mode is more useful for the determination of enrichment at 
different positions in a given molecule.
Chemical Ionization. A reagent gas is ionized at a 
relatively high pressure, about 1 Torr, and the resulting 
reagent gas ions react with sample molecules to yield charged 
products. Little fragmentation occurs in this type of 
ionization since little internal energy is imparted to the 
ion produced in this type of ionization. This method is 
useful for determining molecular weight or total mass 
enrichment resulting from stable isotope tracers, without 
differentiation of the position in the molecule in which the 
heavy isotope is located.
Other Methods. These are new techniques of ionization 
which involve desorption i.e the molecule is both evaporated 
from a surface and ionized. These techniques are of limited 
application in metabolic research as they have been designed 
to enable the analysis of larger molecules.
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3.6.4.B MASS ANALYSER
Various mass analysers exist, but the ones which are
useful in metabolic studies employ either a quadrupole or 
magnetic mass analyser,
Quadrupole, This mass filter consist of four parallel 
circular rods that radiate an electrodynamic field. Opposite 
rods are electrically connected, and the applied voltage 
consist of a constant DC component and a ratio frequency (RE) 
component. Because of the oscillating field, a positive ion 
entering the quadrupole region will oscillate between the 
electrodes at a specific RF. The quadrupole mass filter will 
thus allow ions of certain mass to pass through depending on 
the magnitude of the field.
Magnetic Mass Analyser. This type of analysers is usually 
used with IRMS instruments. Either a permanent magnet or an 
electromagnet is used to deflect the molecular ions according 
to their masses. Each mass is different enough that the major 
and minor isotopes of the gaseous molecular ions can 
simultaneously be collected on spatially separate detector 
plates.
I
3.6.4.C ION DETECTION
The detection of ions in GCMS work is most frequently 
enhanced with an electron multiplier. The ions that exit from 
the mass analyser bombard the surface of the electron 
multiplier and cause electrons to be ejected from i;t's II
f
S.
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metallic surface and these electrons in turn cause the 
ejection of more electrons until the signal of each ion is 
amplified lo^-io'^ times. Both negative and positive ions can 
be detected that way. The amount of amplification depends on 
the energy and mass of the incident ion, the age and 
condition of the electron multiplier and the voltage applied 
to electron multiplier.
I
I
3.6.4.D DATA HANDLING
Interfacing with a computer is required in order to 
collect and process the generated data. A computer can be 
programmed to collect, store and manipulate data in several 
different ways. For isotopic studies there are two modes that 
are most useful. One type allows for scanning and storing of 
several entire spectra. The other is for repeated scanning of 
only selected ions from a spectrum and is called SIM, which 
stands for selected or specific ion monitoring.
3.6.5 ISOTOPE RATIO MASS SPECTROMETRY
The IRMS is designed to measure isotopic abundances of 
elements in gaseous form. Thus when H^, ^^N, and '^^ S
are used as tracers, their enrichment is most commonly 
determined from hydrogen and nitrogen gas, carbon dioxide and 
sulphur dioxide. This instrument is capable of detecting a 
level of 10 parts per million which is quite adequate for the 
measurement of ^H/^H, 13^/12^^ 1Qq ^16q IS^ ylijsj ratios in
metabolic studies.
■■■ ;■
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The inlet system of the MS is connected to the gas holding 
cells which contain the sample gas and the reference gas. The 
gas molecules stream from the holding chamber through the 
molecular leaks into the MS which is under high vacuum. The 
capillary leak lines lead to a pair of switching valves that 
admit the sample and the reference gas alternatively to the 
ion source. All the MS conditions are maintained at the same 
settings during the analysis of both sample and reference, 
and if the true ratio of the reference is known, then an 
absolute ratio for a sample can be determined. Once in the 
source, the gas molecules are bombarded by electrons that are 
emitted from the filament wire. Some of the molecules become 
positively charged and past a series of focusing lenses into 
the analyser section of the MS. The molecular ions are 
deflected by the magnet toward the ion detector. The ion 
detector is usually a Faraday cup or electrometer amplifier. 
Data handled by a computer or strip chart recorder.
3.6.6 COMPARISON BETWEEN GCMS AND IRMS
The GCMS and IRMS are complementary instruments, and both 
are useful for performing metabolic tracer studies. The main 
advantage of the GCMS analysis is the almost limitless 
variety of samples that can be analysed while small number of 
pure gases can be analysed by IRMS. Using GCMS is less 
tedious for any compound other than pure gas and smaller 
samples are needed than IRMS.
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The advantage of the IRMS is the greater precision of 
measurement of isotopic enrichment. A comparison between GCMS 
and IRMS is given in table 3.6.1(46,107).
TABLE 3.6.1 Comparison between IRMS and GCMS.
Ii.s
IRMS GCMS ■1
II
Sample type Pure gas
Sample size
Mass analyser
Precision
Enrichment range
10-3-10-6 gm
Magnet
± 0.0001
0%-0.5%
Volatile organic 
compound
10-7-10-10 gm
Quadrupole
±0.5
0 .2 % - 100%
I
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CHAPTER 7 
SMALL INTESTINAL MUCOSAL SAMPLING
3.7.1 INTRODUCTION 
Biopsy material from the mucosa of human small intestine
free of post mortem autolysis or surgical trauma did not 
become readily available until 1956 (111). Prior to that
small mucosal specimens were obtained by lapratomy or post 
mortem (112). Later on Crosby and Kugler introduced an 
intestinal biopsy capsule capable of removing mucosal 
specimens from any level of the intestinal tract (113). 
Subsequently many modifications and additional biopsy tubes 
have been described (114). The peroral small bowel biopsy has 
altered the concepts of pathological changes and provided an 
important tool for investigation of certain physiological 
processes (115).
The introduction of fibreoptic pan-endoscope had 
undoubtedly revolutionised the examination of the 
gastrointestinal tract and opened a new chapter in 
Gastroenterology in the early 1970s (116).
3.7.2 CROSBY KUGLER BIOPSY CAPSULE
This intestinal biopsy capsule obtains samples of mucosa 
from the small bowel by oral passage of the capsule and 
attached tubing to the area to be biopsied. Suction created 
by a syringe pulls mucosa into a port on the side of the
capsule and triggers the knife. :
I1
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3.7.2.A COMPONENTS OF THE CAPSULE
The components of the Crosby Kugler capsule are shown in 
figure 3.7.1.
These components include; the cylinder which contains two 
holes, one for obtaining mucosal specimens and the other hole 
is attached to the polyethylene tubing. The knife is a 
cylindrical block with a blade on one edge and works by cock- 
and-trigger mechanism. The knife has a space to fit the 
screw which secure the spring on assembling the capsule.
The dome is the top of the capsule covering the open end of 
the cylinder. When the capsule is assembled, a latex rubber 
diaphragm is used to separate the cylinder and dome. A 
polyethylene tubing is attached to the cylinder and acts as a 
transmitter of suction to the capsule as well as serving as 
the means of retrieving the capsule after taking the biopsy. 
Other components are, a ring clip to hold the capsule, 
hypodermic syringe to inject saline and air and to develop 
suction.
In our studies we used Crosby Kugler capsule, adult model 
(Quinton, Seattle, Washington 98121, USA) with a diameter of
9.5 mm and a port diameter of 3 mm. The polyethylene tubing 
we used was 5 feet long, inner diameter of 0.055 inch and 
outer diameter of 0.075 inch. s
/#
ft
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Figure 3.7.1 Components of Crosby Kuglar capsule
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3.7.2.B ASSEMBLING AND PASSING THE CAPSULE
The knife and spring assembly are dropped into the 
cylinder. The knife is then cocked by turning anti-clockwise 
and a circular piece of latex rubber diaphragm with a 
diameter of 2 cm laid across the open end of the capsule. The 
latex rubber diaphragm converts the dome into air-tight 
chamber and acts as a gasket binding the dome and the 
cylinder together. The dome is then pressed into the capsule
I
.
and secured in it's place with the ring clip. The capsule 
assembly then checked for leaks or mechanical problems which 
might prevent in vivo firing. Patient then asked to swallow 
the capsule with the tubing. A radio-opaque guide wire is 
threaded into the tube to make it stiffen and help passing 
the capsule quickly. Once the capsule is in the stomach the 
position is verified by fluoroscopy. The wire is removed and
the capsule is allowed to pass through the pylorus. Sometimes
-we need to give the patient metoclopramide {Maxolon, Beecham
%
Research, Hertfordshire, England) 10 mg intravenously to 
speed the passage of the capsule.
3.7.2.C TAKING MUCOSAL BIOPSIES
The capsule is fired when it reaches the desired location 
which is 10 cm distal to the ligament of Trietz (Figure :t■I3.7.2), verified by fluoroscopy. Normal saline is injected 
first to clean the tubing, then air injected to clear the 
saline. The capsule is fired by applying suction with the 
syringe and creating negative pressure to suck the mucosa 
inside the capsule and trigger the knife. The capsule is
Is
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removed gently, opened and mucosal specimen retrieved. The
biopsy is teased onto a piece of mono-filament mesh with the 
villus side up. A small portion is cut, weighed and sent for 
dissacharidases analysis. The rest of the specimen is sent 
for histopathology.
3.7.2.D DISCUSSION
The original design of the capsule has been modified by 
replacing the original spring with a simple one to simplify 
it'sj assembly. The knife block was also modified to ^
accommodate the new coil spring (117).
The use of a guide wire in the polyethylene tubing has many 
advantages. It assists the passage and positioning of the
capsule making the procedure quicker and minimized patient's
discomfort (117,118,119,120).
The use of Crosby Kuglar capsule is quite safe, however, 
occasionally some difficulties might be encountered. The 
capsule might be slow to progress or difficult to withdraw 
out through the pylorus. Changing the patient's posture or 
the use of metoclopramide (Maxolon) and hyoscine-N- 
butylbroraide (Buscopan) usually overcome these problems 
(119) . We have not encountered any of the rare clinical 
complications with using this capsule, some of these 
complications are, abdominal pain, pyrexia and gastro­
intestinal bleeding. Although small bowel perforation with 
fatal outcome had been reported (121,122), but this is very 
rare indeed. Some people found the use of a smaller capsule 
easier and less unpleasant to swallow by patients (123).
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3.7.3 GASTROINTESTINAL ENDOSCOPY
The idea of direct visual examination of the gastro-
-'7
intestinal mucosa dates back to the 1870s, when rigid scopes
were used. It was only during the 1960s fibreoptic 
instruments for direct visual examination of the gut were 
being developed (124). With the modern scopes most endoscopic 
examinations are well tolerated and can be performed on an i 
outpatient basis nowadays using only light sedation. The 
ability to take mucosal tissue specimens is a crucial part of 
endoscopy. The procedure is carefully explained to the 
patients and a formal written informed consent is obtained i 
from the patients.
The scopes we used were; forward viewing pan endoscope 
Olympus GIF XQ 20 for upper gastrointestinal endoscopy and 
paediatric colonoscope, Olympus PCF for ileoscopy (Key Med 
Ltd, South end-on-Sea, Essex, England), Patients were sedated 
with slow intravenous (IV) injection of 5-10 mg midazolam 
(Hypnovel, Roche Products Limited, Hertfordshire, England). 
During the procedure oxygen was given via a nasal oxygen 
cannula (Universal Hospital Supplies LTD, Southgate, London, 
England) at a rate of 4 1/rain. Patients pulse rate and oxygen 
saturation were monitored during the procedure using pulse 
oximeter (Ohmeda Biox, HOC Health Care, Louisville, USA).
il
,3.7.3.A MUCOSAL BIOPSY SAMPLING
Full endoscopic examination was performed before taking 
biopsy to assess the intestinal mucosa. Then the duodenal
with according to the protocol as outlined in chapter 8.
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mucosa was biopsied distal to the ampula of Vater and the 
terminal ileum was biopsied within the distal 50 cm from the 
ileostomy stoma (Figure 3.7,2). The biopsy forceps we used 
were FB-25 K (Key Med, South end-on-Sea, Essex, England) 
which is the standard fenestrated type compatible with the 
instruments we used. Intestinal mucosal samples were dealt
3.7.3.B DISCUSSION
Fibreoptic endoscopy is a safe and well tolerated 
procedure, however certain precautions need to be observed to 
avoid potential hazards. These hazards include oversedation, 
adverse reaction to the drugs used and cardiac arrhythmias 
particularly in the elderly. Oxygen delivery and vital signs 
monitoring are essential to avoid these complications. Due 
care must be paid to the cleaning and disinfection procedures 
of the scopes to avoid transmission of infections such as
:V::salmonella and hepatitis among other infections. Other rare 
complications such as i Perforation, I Ii\paction of the endoscope V  
and bleeding had been reported during advanced therapeutic 
procedures, under emergency circumstances and in the presence 
of risk factors such as impaired coagulation and portal 
hypertension (124),
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Figure 3.7.2 Diagram of the stomach and the small bowel 
showing the sites of mucosal biopsies obtained.
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3.7.4 HANDLING OF MUCOSAL BIOPSIES
The biopsy specimens were obtained from the small 
intestinal mucosa and sent for histopathology including 
histomorphometry, assay of disaccharidases activity and 
determination of protein and nucleic acids composition as 
well as the free intracellular and protein bound tracer
enrichments.
3. 7. 4. A Histopathology,
Distal duodenal mucosa and terminal ileal mucosa were 
biopsied using fibreoptic endoscopy. Crosby Kuglar capsule 
was used to biopsy the jejunal mucosa. Specimens were sent to 
the pathology department in Buin's solution. The jejunal
biopsies were retrieved from the capsule and teased onto a
; opiece of mono-filament mesh with the villus side up, after 
taking a small portion for disaccharidase activity. The 
mounted specimens were then dropped in the fixative (Buin's) 
solution with the villus side down and the mesh up to prevent
detachment of the specimen from the mesh. Specimens obtained
by biopsy forceps were dropped directly in the fixative 
solution.
3.7.4.B Di saccharidases Activity.
A portion of the jejunal biopsy was weighed quickly and 
freezed under -20^C for disaccharidase activity assessment. 
Two distal duodenal biopsies were also taken and dealt with 
in a similar way. The average weight of these specimens was 
10 mg.
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3.7.4.C Protein, Nucleic Acids and Free and Protein Bound 
Tracer Enrichment.
Mucosal biopsies from the terminal ileum, distal duodenum 
and Jejunum were obtained and weighed. They were transported 
in liquid nitrogen and kept frozen at -70^0 until analysis.
II
t
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CHAPTER 8
DEVELOPMENT OF A TECHNIQUE OF MEASURING MUCOSAL PROTEIN
SYNTHESIS
•i
3.8.1 MEASUREMENT OF PROTEIN SYNTHESIS
The methods used to measure protein synthesis in animal 
and man depend on the fact that proteins are synthesised from 
free amino acids only. The rate of protein synthesis can be 
measured as either the rate of incorporation of a labelled 
amino acid into protein or the decay rate of labelled 
proteins (37). The methods available now for studying protein 
turnover (synthesis and breakdown) are, whole-body protein 
turnover methods (125), methods for regional amino acid 
metabolism and protein turnover (126) and measurement of 
protein synthesis by precursor (amino acids tracer) 
incorporation techniques (127). My work, which is described 
in this thesis, is concerned with the tracer incorporation 
techniques to measure the small intestinal mucosal protein 
synthesis and whole-body protein turnover.
3.8.2 THE PRECURSOR POOL FOR PROTEIN SYNTHESIS
In the 1950s there was a number of attempts to ascertain
the source of amino acids for protein synthesis, whether 
proteins were synthesized from free amino acids or free pre­
existing proteins or peptides. It was concluded that proteins 
were made de novo from free amino acids and this conclusion 
is accepted today (128).
I
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such as bacteria, yeast and moulds served as a basis for 
studies on more complex systems (129,130,131,132).
1
Investigations of amino acids pool in single-cell organisms
Then different tissues were used for in vitro studies such 
as small muscles (133, 134), pancreas (135), :^e1^al bones
V .
(136,137), liver slices both from animals (138) and man 
(139) and submandibular glands (140). There was no adequate 
means of assessing the viability of the tissue and was 
difficult to prove the uniformity of the metabolic process 
and isotope labelling within the tissue as the substrates 
were supplied by diffusion from the media. A reliable in 
vitro organ culture technique had been developed for small 
intestine (141). In these studies it is impossible to 
determine the effect of various metabolic stimuli on the 
protein turnover. Therefore studies on perfused organs were
developed where the circulatory system is intact so that 
metabolites and tracers can reach the cells by their normal 
route. Organs perfused in these studies were liver 
(142,143,144) and heart (145,146).
Experiments in the whole animal in vivo have confirmed the 
results obtained on perfused organs in vitro. In this type of 
studies compartmentation of amino acids in different tissues 
have been demonstrated (147). In some tissues it has been 
possible to measure specific activity of the amino acids 
bound to tRNA which is the real precursor of protein 
synthesis (148,149,150). The tracers were given via different
7 2
routes and methods including continuous feeding 
(151,152,153), intraluminal perfusion (60,154), intravenous 
injection (155,156,157) constant intravenous infusion 
(128,158) and intraperitoneal injection (159).
The use of radioactive tracers in man is not justified 
particularly with the increasing sensitivity of modern mass 
spectrometers to measure the stable isotopes enrichment 
(Chapter 6). Various routes and methods were used to deliver 
the tracer amino acids in human studies such as; single IV 
injection, flooding dose IV injection, Continuous IV 
infusion. Primed Continuous IV infusion. Continuous IG 
infusion and Primed Continuous IG infusion. Currently, 
protein synthesis is measured predominantly by using a 
primed-constant infusion or flooding dose of labelled 
precursor (46).
3.8.3 CHOICE OF AMINO ACID TRACER
When a labelled amino acid is delivered to the body it is 
rapidly distributed in the body fluids from which it is 
incorporated into protein. The method of continuous infusion 
of labelled amino acid enables rates of protein synthesis to 
be calculated from the infusion of any amino acid, but a 
suitable choice will optimize the speed and accuracy of the 
measurement. A number of factors determine the choice of a 
tracer amino acid. It should not have metabolic pathways of 
quantitative importance other than synthesis of protein and 
oxidation. The time required to reach a plateau enrichment
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with a continuous infusion method is short although can be 
overcome by giving a prime dose. Other factors are not so 
important nowadays with the availability of sensitive 
analytical methods. Among these factors is the contamination 
of the amino acid with the D isomer. The method used to 
separate the amino acids has an effect as well. Enzymatic 
method is quicker and cheaper than separation by column 
chromatography on an automated amino acid analyser although 
this latter method is more accurate (37) . It is immaterial 
whether the tracer amino acid is essential (127,160) or non- 
essential (161) as long as the appropriate precursor pool can 
be identified and the precursor labelling measured (35). It 
has been shown that similar results obtained using both
types of amino acids (162,163).
Leucine has been used as a tracer in many studies because 
it is rather abundant in protein at about 8-10% (35) and its
free pool size is relatively small so it can be rapidly
labelled and tracer incorporation into protein will be 
efficient (164). A general assumption of tracer methodology 
is that there is no recycling of tracer and any amino acid
that enters the protein pool is lost irreversibly in the time
frame of a normal tracer experiment (165). It has been 
claimed that for leucine, recycling of label from protein can 
be a problem within several hours of tracer infusion 
(166,167). However, research has shown this not to be the 
case (165) and it seems safe to assume that there is little 
tracer recycling in an experiment of normal duration (46).
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There have been relatively few studies of the metabolism 
of valine (168,169,170) compared with studies of leucine 
metabolism. The ketoacid of valine, alpha-ketoisovalerate 
(KIV) offers the same technical opportunity to sample 
intracellular enrichment in a similar way to leucine and 
alpha-ketoisocaproate (KIC). The rates of plasma flux and 
oxidation of valine are similar to those of leucine but the 
transamination equilibrium favours leucine transamination 
over valine by five fold.
Phenylalanine is not metabolized peripherally and it is 
virtually entirely metabolized by the liver (46).
3.8.4 CHOICE OF TRACER DELIVERY TECHNIQUE
As mentioned earlier, currently, protein synthesis is 
measured either by using the primed-constant infusion or the 
flooding dose injection technique. In both methods the 
assumption is that there is a homogeneous metabolic nitrogen 
pool of which plasma constitutes a part (127,46).
In their study, Halliday and McKeran achieved a plateau 
labelling of If^^N]lysine in 14-16 hours (127) therefore to 
overcome this problem another amino acid with a smaller free 
pool size, leucine was used and a prime dose was injected 
before the constant infusion to enable rapid achievement of 
plateau enrichment of the precursor (160,164). In this method 
usually small dose of 99% level of labelling used e.g 1 mg/kg 
prime dose followed by 1 mg/kg/h for 4 h. The use of priming 
dose was first described in 1954 (171) in conjunction with a
constant infusion of tracer. The advantages of reducing the
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time to reach isotopic equilibrium are to make it possible to 
study subjects within a few hours without interfering with 
patient care and also to avoid the possible changes in the t 
physiological state of the subjects studied if the infusion 
takes long time, thereby altering the kinetics of the 
substrate that are being studied. The final equilibrium value 
is not affected by the prime dose, only the time to reach it i 
is shortened. The ultimate plateau enrichment is the sum of 
the decline in the enrichment of the prime dose and the rise 
in enrichment resulting from the continuous infusion. At 
plateau enrichment (isotopic equilibrium), the rate of 
appearance of the unlabelled substrate is equal to the rate 
of tracer infusion divided by the plateau enrichment (46). In 
this method there is uncertainty in the estimation of the 
labelling of the precursor pool and difficulty in identifying 
the true precursor enrichment for the calculation of protein 
synthesis, hence there is a limit to the accuracy of the 
calculated values (35,46,164).
The so called flooding dose technique tries to solve the 
precursor problem by bringing all of the free amino acid 
pools (intra and extra cellular compartments) including the 
pool that is used for charging tRNA to a common value of 
labelling, thus enabelling rates of protein synthesis to be 
calculated with minimum error (37). A mixture of large dose 
of tracer amino acid at a relatively low level of labelling 
(20%) and a tracee amino acid to a total dose of 50 mg/kg 
body weight is given intravenously over a few minutes. Target 
tissue is biopsied after about 90 minutes and analysed by
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usual methods (172). Theoretically this method should
eliminate uncertainty regarding precursor enrichment and it 
should be possible to use only one plasma enrichment 
measurement to quantify the true precursor enrichment. 
Another advantage is the potential for rapid and convenient 
measurement of protein synthesis rates in human under 
hospital conditions (46,172). This technique was adapted from 
the original use of the radioactive tracers (150). On the
other hand, there are potential problem with this technique
as it assumes that the large dose of the amino acid injected,
well in excess of the total body free pools of that amino
acid, will have no effect on the rate of protein synthesis. 
Furthermore, the assumption that there is no delay in the
incorporation of tracer amino acid from the free pool to the 
protein bound pool i.e protein synthesis is instantaneous 
(46). Using this technique, (172,173,174) the rates of 
protein synthesis obtained have been approximately twice 
those obtained with the primed-constant infusion method 
(175,176). To investigate this, simultaneous measurement of 
incorporation of continuously infused tracer into protein
before and after flooding dose of amino acid was performed.
The results suggest that the flooding dose itself may 
introduce artefacts in the measurement of protein synthetic 
rate (175,177). Other examples of an apparent increase in the 
rate of tracer incorporation as a result of flooding-dose 
protocol can be found for albumin (176), non-albumin protein 
in blood (35) and for collagen (41). The difference is not 
attributable to an analysis problem as the Garlick group are
.■ '   “
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themselves able to reproduce the same values obtained by 
others using the constant infusion technique. One possible 
explanation is that the large dose of leucine induces insulin 
secretion which stimulate protein synthesis and which happens 
before taking the first blood sample and by that the peak of 
insulin secretion was missed by Garlick group (164).
3.8.5 THE PRECURSOR PROBLEM
The ideal precursor to measure the protein synthetic rate 
is the arainoacyl tRNA (35,37). There are difficulties in the 
measurement of the tRNA. The free tRNA pool is extremely 
small and the rate of protein synthesis relatively fast, the 
half time of tRNA pool turnover should be correspondingly 
small and was calculated to be of the order of seconds (178). 
Another problem is that direct measurements of the tRNA 
demand large tissue specimens (1-5 gm) (179) which must be 
handled with special caution because of the small amount of 
tRNA present and jilt's/rapid turnover rate (148). Although the 
plasma KIC labelling is always higher than the intracellular 
leuci(n Enrichment (46, 180), nevertheless, the extent of tRNA
labelling appears to be close to that of alpha-KIC which/laysd v
V 'between venous leucine labelling and the intracellular 
leucine labelling (1'81). It seems now that the labelling in 
various pools as follow; venous leucine 100%, venous alpha- 
KIC 82%, leucyl tRNA 78% and intracellular free leucine 72% 
(182). According to this, any errors in the measurement of 
the rate of protein synthesis cannot be greater than about 
20% (35).
a't-j
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CHAPTER 9
EXPERIMENTAL DESIGN, CALCULATIONS AND STATISTICAL ANALYSIS
EXPERIMENTAL DESIGN
3.9.1 SUBJECTS
Healthy volunteer subjects and patients with various 
gastrointestinal diseases were recruited during the course of 
this work. Patients with untreated coeliac disease, alcoholic 
liver disease and ulcerative colitis treated with total 
colectomy and ileostomy were included in the studies. Both 
male and female adults were studied in the post absorptive
state i.e asked to fast from 2100 on the evening before the
study, which was carried out between 0900 and 1400 of the
following morning. There was no adaptation to a standard 
diet prior to the studies but the subjects and patients ate 
their accustomed diet. These studies were performed in the
Department of Gastroenterology, Glasgow Royal Infirmary 
University NHS Trust. Each subject gave written consent after 
a full explanation of the study. All the studies were 
approved by the local ethics committee of the Royal 
Infirmary, Glasgow.
3.9.2 TRACERS
The stable isotope tracers L-[1~^3q jpeucine and L-[l- 
13c]valine (99 Atom %) were obtained from MassTrace, Woburn, 
MA. Once weighed according to the protocol and subject's 
weight, the powder was dissolved in a beaker with the
2,
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appropriate amount of sterile, non-pyrogenic 0.9% NaCl 
solution (150 mmol/1) (Baxter Health Care Ltd, Thetford 
Norfolk, England), before administration. The solutions were 
sterilized by passage through a 0.20 micron filter (Acrodisc- 
DLL, Gelman Sciences, USA) .
3.9.3 EXPERIMENTAL PROTOCOL
The patients were studied in the morning following an 
overnight fast, they neither received food nor drink during 
the study and remained serai-recumbent in a thermometer 
environment room temperature (25-27 ^C). Venous blood samples 
were taken from a 14G/2 mm outer diameter cannula (Venflon-2, 
Viggo AB, Helsingborg, Sweden) placed retrogradely in an 
anti-cubital vein and maintained patent by heparin IV flush 
solution 10 unit/ml (Heplok, Leo Laboratories Limited).
Before sampling, 3 ml of venous blood was withdrawn and 
discarded, then 5 ml of venous blood was withdrawn and 
centrifuged at 2.8 x 1000 RPM at room temperature for 20 min
using lEC Centra-3 centrifuge (Bedfordshire, England). 2 ml
of separated plasma was collected and kept in liquid 
nitrogen at -180^C in 2.0 ml cryogenic vials (Corning, N.Y.
d;
14831). Priming doses of either L-[I-^^q ]peucine or L-[l-
_13c]valine Img kg  ^ body weight were given IV over one rain in 
25 ml of 0.9% NaCl via 0.20 micron filter and using 18G/1.2 
mm outer diameter cannula followed by a constant infusion of 
the same tracer at a rate of Img kg"l body weight h~^ over 4 
h time using 120 ml of 0.9% NaCl (30 ml/h) . The infusion was 
controlled with IVAC-531 volumetric infusion pump (VAC-House, I
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Harrow, England). Simultaneously the complementary tracer 
(either L-[i-^^C]valine or L-[l-^^C]leucine) was given via 
the enteral route. A priming dose of 1 mg kg“  ^ body weight 
was dissolved in 50 ml 0.9% NaCl and delivered over two min 
via a naso-gastric tube, XRO-Paediatric Duodenal tube-39306 
(Vygon, Ecouen, Prance) followed by a constant infusion of 
the same tracer dissolved in 480 ml of 0.9% NaCl at a rate of 
1 mg kg"l body weight h"^ for 4 h (120 ml/h) and delivered 
via a volumetric pump (MHRE-7 Watson - Marlow Limited, 
Cornwall, England). The position of the naso-gastric tube was 
checked radiologically by an image intensifier and infusion 
only started after getting a satisfactory position of the 
tube. Figures 3.9.1 to 3.9.4 illustrate the experimental 
protocols followed in the studies.
A group of control subjects and the patients with coeliac 
disease received two tracer amino acids via the IV and the IG 
route simultaneously and had an upper gastrointestinal 
endoscopy to obtain distal duodenal biopsies at the end of 
the tracer infusions (Figure 3.9.1).
Another group of healthy volunteers received IV L-[l- 
^^c]leucine only, but these subjects had two endoscopies done 
to obtain intestinal mucosal samples at various times during 
the tracer infusion. This protocol enabled us to assess the 
pattern of tracer incorporation into the intestinal mucosa 
(Figure 3.9.2) .
The alcoholic liver disease patients received IV infusion 
of L-[1-^^C]leucine only and had one upper gastrointestinal 
endoscopy done to obtain duodenal biopsies (Figure 3.9.3).
■  ^■    ^
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In the ileostomy group I obtained small intestinal mucosal 
biopsies from two sites i.e jejunum and ileum at the end of 
the IV tracer infusion (Figure 3.9,4).
The wet weight of the mucosal biopsies was >50 mg to 
ensure the availability of adequate amount of tissue for 
analysis. These samples were immediately frozen in liquid 
nitrogen, then subsequently stored, with the plasma samples, 
at -70^0 until subjected to analysis. Further biopsies were 
taken for histology, fixed in Buin's solution, and for 
dissacharidases assay. Venous blood samples were taken at - 
15, 0, 60, 120, 180 and 240 minutes respectively and
separated plasma kept in liquid nitrogen.
i
/|:
3.9.4 13c ANALYSIS
Analysis of enrichment in plasma and neutralized
perchloric acid (PCA) extracts of freeze-dried, ground 
mucosal tissue were determined by GCMS. As urea interferes 
with GCMS, we had to remove it by incubation with Jack-bean 
urease at 37^0 for 15 minutes. Plasma amino acids were 
extracted with methanolic HCl (4:1, v/v), the solvent removed 
by evaporation, and then the residue redissolved in pyridine 
before preparation of t-butyldimethylsilyl (t-BDMS) 
derivatives by reaction with N-methyl-N-(L-BDMS) trifluoro- 
acetamide (Regis Chemical Company, Morton Grove. IL, USA) 
(183). GCMS was carried out on Finnigan 1020B instrument 
(Finnigan MAT Ltd, Hemel Hempstead, UK), fitted with a 20 m x 
0.2 mm inner diameter OF WCOT chemically bonded fused silica
I£
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column {Pierce UK Ltd, Cambridge, UK), with temperature 
programmed from 110 to 270^0 at 15^C/min after a 1 rain lag. 
Decane was used as solvent. The injector temperature was
280^0 and injection, in the splitless mode, was complete in 
30 s. The carrier gas was helium at 50 kPa, The mass
spectrometer was operated in the electron impact mode with an 
ionization energy of 70 eV, The enrichment of [ l-^^C]leucine 
and [ 1-^3qjY^p2.ne were determined by monitoring m/z 302 and 
303. The enrichment in ketoisocaproate (KIC) and
ketoisovalerate (KIV) were determined by similar methods 
using 0-trimethylsilyl quinoxalinol derivatives ( 1 8 4 )  and
monitoring m/z 232 and 233.
To determine the ^^C enrichment in protein bound leucine 
and valine, protein from freeze-dried, ground mucosal samples 
was repeatedly washed with PCA, acid hydrolysed (6M HCl) and 
amino acids were separated by preparative gas chromatography 
( 1 8 5 ) ,  which is rapid and simpler than the classical ion- 
exchange chromatography ( 1 8 6 ) .  CO2 was liberated by 
ninhydrin, which is a powerful oxidizing agent causes 
oxidative decarboxylation of alpha-amino acids producing CO^, 
NH3 and an aldehyde with one less carbon atom than the parent 
amino acid ( 1 8 7 ) . The ^^C enrichment was determined using the 
automated breath gas system optimized for small quantities of 
CO2 ( 1 8 8 )  and isotope ratio mass spectrometry. We also used 
the automated ^^C analyser (ANCA) Tracer Mass and
RoboPrep-G (Europa Scientific Ltd, Crewe, UK). The ANCA 
system reduced the cost of analysis and improved the
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laboratory productivity. It usually needs minimal sample 
handling as well as smaller samples.
Lipid material then was removed from the pellet in a series 
of solvent washes. Protein is then solubilised in 0.3 M NaOH 
in a water bath at 37*^ C for 60 min. An aliquot was removed 
for the measurement of protein concentration using Polin's 
reagent as outlined by Lowery (189). The protein then 
reprecipitated by the addition of 2 ml IM PCA.
3.9.6 NUCLEIC ACIDS COMPOSITION
3.9.5 PROTEIN COMPOSITION Î
The mucosal tissue biopsies were transported and stored in 
liquid nitrogen or in -70^0 freezer prior to analysis. 
Minimum weight of 50 mg was ground to powder, in liquid 
nitrogen, and was transferred to a glass tube containing 3 ml 
of ice cold 0.2 M PCA and centrifuged after 10 min. The free 
amino acids and ketoacids were extracted in the supernatant.
■ : 
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RNA was extracted using 0.2M PCA and DNA extracted with 2M 
PCA at 70^0 for 60 min. The protein was re-pelleted by 
centrifugation and hydrolysed by 6M HCl for ^^C-analysis. The 
determination of nucleic acids was by dual wavelength
Iultraviolet absorption method (190); RNA from UV absorbance 
of 260 nm and 275 nm, and DNA from UV absorbance at 268 nra 
and 284 nm, on a UV spectrophotometer using quartz Cuvettes 
and PCA as a reagent blank.
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3.9.7 HISTOLOGY
Intestinal mucosal specimens were fixed in either 10% 
formalin buffered saline or Buin's solution, embedded in 
paraffin wax and 4 u sections prepared for light microscopy. 
Sections were stained with haematoxylin and eosin. Mucosal 
histology was considered normal when the villous pattern was 
intact and villus to crypt ratio greater than 2:1 in the 
absence of any increase in the number of inflammatory cells.
Other methods performed, such as histomorphometry, 
disaccharidase assay, serum vitamin B^2 & folate and red cell 
folate are discussed in the relevant chapters.
CALCULATIONS
The measurement of protein synthesis by the determination 
of the rate at which a precursor is incorporated is termed 
the fractional synthetic rate (FSR) . This refer to the rate 
of syntheses, e.g gm/day divided by the total protein pool
size, gm. In the steady state, the fractional degradation
rate, is equal to FSR {synthesis = breakdown). The value
for k^ has no necessary relationship to k^ which is the rate 
parameter from the amino acid pool to the protein pool and is 
quite different from FSR. However, the optimal technique to 
measure the FSR of a specific protein using the primed 
constant infusion method of an amino acid tracer is to
determine the pattern of enrichment of the protein bound
amino acid and to use compartmental modeling to calculate the 
rate parameter relevant to protein turnover. In this case it
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is assumed that, if precursor enrichment is constant, then 
over the first several hours of infusion the tracer will be 
incorporated into protein in a linear manner. In this case 
the FSR (kg, h”f) can be calculated using the expression;
kg (%h-l) = (E^ - EQ/Ep) X 1/t X 100
where E^ is the enrichment in tissue protein at time t, Eq is 
the baseline enrichment and Ep is the enrichment of the 
precursor (46). The calculation of the FSR by the short-term 
constant infusion technique has many obvious practical 
advantages, but is limited by the need to identify the true 
value of precursor enrichment (Ep) (Chapter 8). The precursor 
we used in our calculation was the intracellular tracer amino 
acid enrichment.
Whole-body protein breakdown was calculated using the 
expression; Protein breakdown (umol of leucin /kg/h) = F 
(umol/kg/h)/E^2c ^ 100%, where F is the rate of leucine
infusion and E^^c is the enrichment of the ketoacid (191).
STATISTICAL ANALYSIS
Values were expressed as means ± SD and average (range). 
Statistical analysis by means of Wilcoxon's ranking test for 
the non parametric, unpaired data (Mann-Whitney test), paired 
and unpaired Student's t-tests, Spearman's rank correlation 
or two-tailed t test as appropriate. Differences were 
considered significant at P values of <0.05.
90
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CHAPTER 10
GUT MUCOSAL PROTEIN SYNTHESIS MEASURED USING INTRAVENOUS AND 
INTRAGASTRIC DELIVERY OF STABLE TRACER AMINO ACIDS
4.10.1 INTRODUCTION
In the last fifteen years the use of stable-isotope 
labelled amino acids has revolutionized the measurement of 
human tissue protein metabolism studied by estimation of
.blood tracer flux and incorporation of tracer amino acids 
into tissue biopsies (46). Although there is a substantial 
interest in human gastrointestinal protein metabolism and 
there are reports of measurement of tracer incorporation into 
normal and diseased gastrointestinal tract tissues 
(39,192,193,194,195) no robust, well validated method exist 
for measurement of mucosal protein synthesis in the small 
intestine in human beings. A question of some significance in 
designing such a method is whether a preferential route of 
entry of amino acids to the synthetic precursor pool, via the 
apical or basolateral membrane, exists in small intestinal 
mucosal tissue, via the apical or basolateral membrane, both 
have been supported by work in animal preparations (154,196). 
Alternatively, the free intracellular pool may simply contain 
a mixture of basolaterally and luminally derived amino acids 
from which precursor is drawn according to the degree of 
mixing (197). Unfortunately no information pertaining to this 
question exists for human gut in vivo.
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4.10.2 AIMS
The aims of this study were; 1) to develop a method that 
would allow measurement of protein synthesis in any 
gastrointestinal mucosal tissue capable of being sampled 
either by investigative biopsy or interoperatively and 2) to 
investigate the effect of route of administration of tracer, 
whether IV or IG, and 3) to compare the measured rates of 
distal duodenal mucosal protein synthesis to previously 
obtained rates in other tissues and the whole body.
4.10.3 SUBJECTS AND METHODS
Seven healthy subjects, six men and one women (age 26 ~ 59 
years, weight 56 - 86 kg) (Table 4.10.1) were studied. All 
subjects were asked to fast from 2100 on the evening before 
the study, which was carried out between 0900 and 1400 of the 
following morning. Before fasting the subjects ate their 
accustomed diet. Each subject gave written consent, which was 
carried out under the auspices of the Ethics Committee of the 
Glasgow Royal Infirmary University NHS Trust. The subjects 
were investigated over a period of 4 h during which stable- 
isotope-labelled tracers L-[1-^^C]leucine and L-[l-^^C]valine 
were infused, 1 mg,kg“l priming dose followed immediately by 
constant infusion of 1 mg.kg“l.h“  ^ either IV or IG. In four 
of the subjects (3 men and 1 women) leucine tracer was given 
IV and valine tracer IG simultaneously. In the three others 
(3 men) the routes of delivery were reversed (Figure 3.9.1). 
There were no differences in body mass index (198) or age in 
the subgroups. At the end of 4 h of infusion, duodenal mucosa
. :;iJv
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duodenal mucosal protein synthesis.
Patient Age-Y Sex Weight-kg Height-cm %Ideal BW
■ :%{
Î
1 57 M 65 158 105.01
2 53 M 85 185 112.58
3 59 M 70 178 98. 18
4 55 M 56 172 82.23
5 26 M 70 180 96 . 69
6 51 F 86 160 148.02
7 47 M 80 173 116.45
I
■Ï'I
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i
% ideal BW : % ideal body weight (198)
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was sampled distal to the ampulla of Vater via endoscopy, as
described before (Chapter 7), to obtain the 50 mg of tissue
necessary for analysis. The endoscopic forceps biopsy 
technique usually required five or six separate samples from 
different mucosal sites. Venous blood samples were taken 
before infusion of tracer and at hourly intervals over the 
period of infusion for the analysis of ^^C in leucine,
valine, KIC and KIV. Plasma was separated by centrifugation 
and immediately frozen for later analysis. The labelling of 
plasma amino acids and keto acids were measured by means of 
standard GCMS technique using t-BDMS derivatives (199). 
Mucosal tissue samples were frozen in liquid nitrogen
immediately upon sampling and were pooled for storage at 
-70^C; they were analyzed for concentration of protein, RNA 
and DNA (190). Total plasma protein from the preinfusion 
samples [precipitated by use of 10% (wt/vol) PCA] was used to 
estimate basal body protein labelling for use in the
calculation of mucosal protein synthetic rate. In our 
experience the background enrichment of human tissue proteins 
from whatever tissue source varies by very little. The 
average basal value for leucine was 17 ± 1% q  over Pee Dee
Belamnite (PDB) and for valine 23 ± 1% q  over PDB. The
labelling with ^^C of leucine and valine in hydrolysed 
protein using preparative GC and IRMS of the COg liberated by 
ninhydrin (185). Values for labelling were expressed as atom 
or mole percent excess as appropriate, and rates of protein 
synthesis were calculated as described in chapter 9. The 
increase in the enrichment in tissue protein over the basal
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value at time t was measured from the actual value of 
labelling in the mucosal protein obtained after 1-4 h of 
infusion which was 250-1,000 % q , depending on the rate of
tracer delivery.
Statistical significance of differences was assessed by 
means of paired and unpaired Student's t-test; significance 
was assigned at the 5% level.
4.10.4 RESULTS
Mean values and their standard errors are presented. 
During IV and IG infusion of [^^C]leucine and [^^C]valine the 
plasma tracer labelling attained plateau values which were 
maintained within 12% for 4 hrs. The plateau values of the IV 
tracer were 5.46 ± 0.25 APE (atom percent excess), 10%
higher than the plateau values of the same tracer given IG,
4.99 ± 0.25 APE, IV vs. IG, (paired t-test) P < 0.01 (Figure 
4.10.1).
The route of tracer administration strongly influenced the
. ■gradient of labelling between the leucine and valine in the 
intracellular water and in the plasma; for IV tracer the 
plasma to intracellular amino acid pool ratio was 1.73 ± 0.16 
but for IG leucine or valine the ratio was reversed 0.65 ± 
0.12, P <  0.002 (Figure 4.10.2).
IG infusion resulted in the attainment of a higher rate of 
labelling of the intracellular mucosal amino acid pool than 
IV infusion with leucine or valine (Figure 4.10,3).
96
Plasma valine
APE 8 i
0 ■180 24060 120
i
Time -minutes
Plasma leucine' 
APE 8
4'
2 - l.V.
60 120
Time -minutes
180 240
Figure 4.10.1 Plasma labelling of valine and leucine tracers
I
97
The extent of incorporation of tracer leucine and valine 
into duodenal mucosal protein was 2.3 - 3 folds higher after 
4 h of infusion of tracer gi^e \IG than when tracer was given '  ^
IV (Figure 4.10.4).
However, when the rates of incorporation were related to 
the extent of labelling of the appropriate tracer in the 
intracellular mucosal water, the rate of protein synthesis in 
the distal duodenal mucosa became indistinguishable at about 
2.5% h“l. Exact rates were 2.58 ± 0.32% h"^ for IV 
administration of tracer and 2.45 ± 0.36% h"^ for IG
administration of tracer (Figure 4,10.5).
I
If the plasma keto acids of leucine and valine obtained 
during IV infusion were used as surrogate indices of the 
intracellular labelling the protein synthetic rate calculated 
were 1.8 ± 0.4% h”l, a value not significantly different from 
that observed using the mucosal free labelling values (Figure 
4.10.6).
IThe rate of labelling of the respective keto and amino
acids with also depended upon the route of
administration. When the tracer was given via the IG route 
the mean keto acid/amino acid labelling ratio was 0.94 ± 0.02 
for alpha-KIC and leucine and 0.93 ± 0.02 for alpha-KIV and 
valine, whereas the respective ratios for the IV routes were 
0.76 ± 0.07 and 0.78 ± 0.02 (Figure 4.10.7).
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Mucosal tissue showed a high concentration of RNA relative 
either to DNA or to protein, indicative of a substantial 
capacity for protein synthesis (Table 4.10.2), The rates of 
protein synthesis expressed in terms of RNA were 0.32 
protein.h”^,mg RNA"^.
TABLE 4.10.2 Mucosal tissue composition and protein
synthetic capacitv.
Protein DNA RNA Prot. synt. capacity
mg.g-1 mg. mg.g“l rag prot.h~^.rag RNA“^
15.24 ± 0.30 0.68 ± 0.04 1.20 ± 0.06 0.32 ± 0.04
4.10.5 DISCUSSION
The observed higher rate of labelling of the mucosal 
intracellular free amino acid pool with tracer amino acids 
after intragastric infusion was not unexpected given the fact 
that the apical membrane of mucosal cells contain 
concentrative Na-dependent amino acid carriers for the 
branched chain amino acids (BCAA) whereas the basolateral 
membrane contains only non-concentrative facilitated 
diffusive carriers (200). Nevertheless, despite the 
substantial differences in the extent of labelling of the 
intracellular and plasma pool of leucine and valine when the 
tracers were administered IG or IV, and despite the 
substantial differences in the absolute extent of labelling
Î
103
of mucosal protein, the rate of mucosal protein synthesis 
calculated on the basis of the intracellular amino acid pool 
labelling were identical.
No information is available regarding the relationship 
between the various free amino acids pools and the labelling 
of leucyl or valyl tRNA in duodenal mucosal protein. We have 
previously found that in the pig, leucyl tRNA in stomach 
mucosa is labelled to an extent which is indistinguishable 
from that of alpha-KIC during primed constant infusion of 
[Ï^C]leucine (201). It may therefore be that calculating 
protein synthesis based on the intracellular amino acid 
labelling (which is probably lower than the aminoacyl tRNA) 
slightly overestimates the true duodenal mucosal protein 
synthesis and that the true rate lies somewhere between a 
rate calculated using plasma alpha-keto acid (for IV infusion 
only) and the intracellular values.
The results suggest that in the post-absorptive state, 
there is no detectable preferential channelling of amino 
acids into protein synthesis from the apical or basolateral 
membrane of the small intestinal mucosal cells. The question 
of whether or not such channelling occurs has been 
controversial, with experimental findings favouring each 
hypothesis (197,154). However, the present results, 
apparently the first obtained from physiological kinetic 
studies in human beings in vivo, tend to support the idea 
that the free intramucosal pool obtains amino acids from a 
variety of sources and that as expected from previous work on 
rats (196), neither the basolateral nor the apical route is
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favoured. Even so, the question may have a different answer 
if asked for the fed state in which the availability of 
luminal amino acids will be greater, and it would be unwise 
to extrapolate from the present findings to other nutritional 
states.
The lower plateau values for plasma labelling for the 
tracers infused via the IG route than the IV route suggested 
that the IG tracers were being diluted to a greater extent by 
amino acids released from protein breakdown, most likely in
.the splanchnic tissue. Such an interpretation was first
applied to similar findings obtained under similar 
circumstances by Hoerr and colleagues (202).
The relative rates of labelling of the keto and amino
acids for the tracers used agrees with the results obtained 
previously by Hoerr et al (202), The results suggest that 
there is little transamination of the BCAAs during their
'passage from the gastrointestinal lumen into the peripheral
blood in accordance with the known low capacities of the gut 
and liver for BCAA transamination (203). i
The fractional rates of protein synthesis observed in the 
duodenal mucosa were high, being some 25-50 times greater 
than those previously observed for muscle (175,204) and also 
about two to three times greater than those determined for 
normal colonic mucosa (39,173,194). It is impossible to 
exactly quantify the total amount of small intestinal mucosal 
protein in order to calculate the absolute amount of protein 
synthesis contributed by the gastrointestinal tract but the 
high rate suggests that mucosal protein synthesis is a major
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contributor to whole body protein turnover. The extent to 
which human mucosal protein synthesis can be modulated by 
physiological influences including nervous, hormonal and 
nutritional effects, remains to be determined.
4.10.6 SUMMARY
We measured the rates of mucosal protein synthesis during 
the simultaneous delivery of [l-^^C]leucine and [l-^^C]valine 
delivered either IV or IG to investigate any influence of the 
route of supply of the tracers. Depending on the route, there 
was marked differences in the gradient of labelling between 
the plasma and intramucosal leucine and valine i.e, for IV 
tracers the ratio was 1.73 ± 0.16, but for IG tracers it was 
0.65 ± 0.12 (p < 0.05). The calculated fractional rates of 
protein synthesis were identical when based on the 
intracellular labelling of the leucin or valine tracer i.e, 
with IV 2.58 ± 0.32 %/h and with IG 2.45 ± 0.36 %/h. The
results demonstrate that a robust and reproducible method of 
measurement of gastrointestinal mucosal protein synthesis has 
been developed and that use of either IV or IG routes of 
tracer administration gives comparable results. The high 
rates measured suggest that the gastrointestinal mucosa 
contributes substantially to whole body protein synthesis in 
normal healthy subjects.
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CHAPTER 11
THE PATTERN OF TRACER AMINO ACID INCORPORATION INTO 
INTESTINAL MUCOSAL PROTEIN
4.11.1 INTRODUCTION
The mathematical approaches for measuring the 
incorporation of labelled amino acid, and release of labelled 
amino acid from, individual protein in body cells or tissue 
follow established precursor-product relationship (37). The 
measurement of protein synthesis by the determination of the 
rate at which a precursor is incorporated in a specific 
protein is currently made by using a primed-constant infusion 
or a flooding dose of labelled precursor (Chapter 8). 
Synthesis of a specific protein is termed the FSR (Chapter 9) 
which (i/S,i in traditional modeling is not necessary related to 
the kg even in the steady state, although the k^ is equal to 
FSR (protein synthesis = protein breakdown). However, the 
value of kg is equal to FSR if the pattern of incorporation 
of the precursor in the protein is linear (46).
4.11.2 AIM
The aim of this study was to check whether the rate of 
incorporation of tracer into small bowel mucosal protein was 
linear in order to validate the method we used to calculate 
protein synthetic rate.
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4.11.3 SUBJECTS AND METHODS
Four healthy subjects 2 men and 2 women (Table 4,11.1) 
were studied. They were infused with IV [ l-^^C ] leucine only. 
In order to measure the enrichment of the label in the 
mucosal tissue we needed to take mucosal samples at various 
points during the 4 h infusion. Each subject had two 
endoscopic procedures and distal duodenal biopsies were 
obtained using biopsy forceps, taking 5-6 separate samples 
from different mucosal sites. Biopsies were taken either at 
1, 2, 2.5, 3 h of infusion, and also at 4 h of infusion.
Blood samples were taken before infusion of tracer and at 
hourly intervals over the period of infusion for the analysis 
of ^^C enrichment (Figure 3.9.2). Plasma was separated by 
centrifugation and immediately frozen with the mucosal tissue 
samples for later analysis. Standard GCMS techniques were 
used to measure ^^C plasma enrichment. The labelling with ^^C 
of leucine in mucosal protein using preparative GC and IRMS.
the oattern of duodenal mucosal tracer incorooration.
Patient Age--Y Sex Weight"-kg Height-cm %Ideal BW
54
24
21
40
M
F
M
F
87
63
62
79
185
166
162
160
115.23 
102.77 
97.95 
135,97
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4.11.4 RESULTS
During IV infusion of [1“1^C]leucine the plasma leucine 
labelling attained a plateau value of 5.5 ± 0.35 APE (mean ±
SE); this level of labelling was reached within half an hour 
of the beginning of our infusion protocol. The slopes of the 
lines for the [l-^^C]leucine incorporation into duodenal 
mucosal protein showed a variance of no more than ± 15%, y =
g
0 . 0 5 0 X  + 0 . 0 4 4 ,  r2 = 0.88 P < 0.01 (Figure 4 . 1 1 . 1 ) ,
suggesting that the rate of incorporation was linear with 
time. Time zero values in the figure were obtained from
basal plasma protein enrichment. Lines show individual 
regressions for 4 subjects for 3 values obtained. The average Î
rate of mucosal protein synthesis calculated in these 
subjects on the basis of the intracellular mucosal leucine 
labelling was 2.6 ± 0.38 %.h“ .^
4.11.5 DISCUSSION
The results of this study indicate that leucine tracer 
was incorporated into gastrointestinal protein to an extent 
proportional to the time of exposure of the tissue to the
IS
'Ï
tracer at least when delivered IV. We have assumed that this 
is also the case for the tracers delivered IG. Any error 
introduced by this assumption is likely to be small given the 
convergence of the values obtained for the rate of protein 
synthesis based on the free intracellular tracer amino acid ■, 
labelling. Therefore the kg calculated in this infusion 
protocol is equal to the FSR when using the expression K 
(%h“l) - (E^ - Eg/Ep) X 1/t X 100.
s
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protein over time.
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4.11.6 SUMMARY
We measured the rate of mucosal protein synthesis and the 
rate of tracer incorporation in the duodenal mucosal protein 
during IV delivery of [l-^^C]leucine, Tracer incorporation 
into mucosal protein was linear with time during a steady 
state when the plasma tracer enrichment reached a plateau 
value. This linear incorporation of tracer amino acid into 
the mucosal protein validates the method we used to calculate 
the FSR.
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CHAPTER 12
ELEVATED RATES OF DUODENAL MUCOSAL PROTEIN SYNTHESIS IN VIVO 
IN PATIENTS WITH UNTREATED CQELIAC DISEASE
5.12.1 INTRODUCTION
Coeliac disease (gluten-sensitive enteropathy, non-tropical
sprue) is characterized by: generalized malabsorption; a
typical, but nonspecific, small intestinal mucosal lesion;
and a clinical and slower histological response to withdrawal 
of gluten-containing foods from the diet. The hallmark of 
coeliac disease is subtotal villous atrophy, abnormal 
epithelial cells on the mucosal surface and increased 
cellularity of the lamina propria (205). Rates of epithelial 
cell renewal and migration in coeliac disease have been 
reported to be increased six fold and the epithelial cells 
lining these crypts contain numerous mitotic figures 
(206,207).
We have developed a safe, reproducible and reliable
method to measure protein synthesis in the gastrointestinal
'
mucosa using branched chain amino acids labelled with 
(Chapter 10) and used it to measure the rates of protein
i:
S
synthesis in the duodenal mucosa in patients with coeliac 
disease. No measurements of protein synthesis have previously 
been carried out in vivo in coeliac patients.
Î
I
i
I
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5.12.2 AIMS
The main aims of this study were; 1) to measure the rate 
of small intestinal mucosal protein synthesis in untreated 
coeliac patients when the tracer was administered by IG and 
IV routes, 2) to compare the results with those results
obtained from normal subjects, and 3) to determine the effect 
of route of delivery on the rate of protein synthesis in 
coeliac patients.
5.12.3 PATIENTS AND METHODS 
Eight patients (51 ± 10 y, 57 ± 11 kg, 160 ± 6 cm) with
newly diagnosed untreated coeliac disease, four men and four 
women (Table 5.12.1) were studied. Each patient gave written
-
consent after a full explanation of the study. Approval for 
the studies was obtained from the local Ethics Committee of 
Glasgow Royal Infirmary,
The criteria for diagnosis of coeliac disease were;
clinical history of chronic diarrhoea with or without the 
passage of watery, pale stools with abdominal discomfort, 
distension and weight loss; subtotal villous atrophy and
.inflammatory cellular infiltration of the lamina propria, 
mainly plasma cells and lymphocytes, in all patients as shown 
on jejunal biopsies obtained by the Crosby-Kugler capsule
,(113); clinical and histological response to the introduction 
of a gluten free diet. None of the subjects studied were
:
taking any additional medication such as non-steroidal anti­
inflammatory analgesics.
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duodenal mucosal orotein synthesis.
Patient Age-Y Sex Weight-kg Height-cm %Ideal BW
î
I
I:î
1 45 F 40 151 74.63
2 65 F 6 4 160 110.15
3 52 F 52 158 91.23
4 52 M 45 158 72 . 70
5 39 M 6 4 167 97.71
6 65 F 67 159 116.52
7 51 M 67 169 100 . 6
8 40 M 65 159 104.50
i
■SiifII'3:1.
,i
.1I
:
f.
% ideal BW : % ideal body weight (198)
!
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L_[l_13c]iQucine and L - [ I - ^ ^ q ] j_ng both 99 Atom %, 
immediately before administration, were dissolved in sterile, 
non-pyrogenic 0.9% NaCl solution and were sterilized by 
passage through a 0.20 micron filter.
The patients were studied in the morning after an 
overnight fast. Venous blood samples were taken, centrifuged 
and separated plasma was kept in liquid nitrogen. Priming 
doses of either L-[l-13c]leucine or L-[l-13c]valine (Img/kg 
body weight) were given IV over one min; a constant infusion 
of the same tracers at a rate of Img /kg body weight/h using 
120 ml of 0.9% NaCl was then continued for 4 h.
Simultaneously, the other tracer (either L-[1-^^C]valine or 
L-[i-13c]leucine) was given via the enteral route. A priming 
dose of 1 mg/kg body weight in 50 ml 0.9% NaCl was delivered 
via a naso-gastric tube over two min followed by a 4 h
constant infusion at 1 mg/kg body weight / h in 480 ml of 
0.9% NaCl (120 ml/h) . After 240 min of continuous infusion, 
upper gastrointestinal endoscopy was performed and multiple 
distal duodenal biopsies were obtained. The range of the
pooled wet weight of biopsies was 58.0-65.1 mg. Further
biopsies were taken for histology and disaccharidase assay. 
Venous blood samples were taken at -15, 0, 60, 120, 180 and
240 min respectively and separated plasma kept in liquid 
nitrogen with the biopsies (Figure 3.9.1).
Biopsy tissue was quickly weighed and transferred for 
storage at -70^C until disaccharidase estimates were done. 
Before assay the biopsy tissue was homogenized in chilled
distilled water and centrifuged. The disaccharidase
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activities (lactase, raaltase and sucrase) were assayed in the 
supernatant by a modification of the Dahlqvist method (208).
The labelling of plasma leucine, valine, alpha-KIC and 
alpha-KIV were measured by means of standard GCMS techniques ■■'i
using t-BDMS derivatives (199). Mucosal tissue samples were 
frozen in liquid nitrogen immediately on sampling, and
samples pooled for storage at -VO^C. The labelling with ^^C 
of leucine and valine in hydrolysed protein was done by using
preparative gas chromatography and IRMS of the CO2 liberated
by ninhydrin as previously described (185). Plasma protein
from the pre-infusion samples was used to estimate basal
body protein ^^C labelling for use in the calculation of
mucosal protein synthetic rate. The pooled mucosal tissue
■samples were analysed for concentration of protein, RNA, and 
DNA (189,190).
We calculated protein synthesis as fractional rate using 
the equation kg (%h-l) = (E^ - E^/E^) x 1/t x 100. The
precursor we used in our calculation was the intracellular
tracer amino acid. The calculation by this equation depends 
on the fact that the tracer incorporation into the protein is 
linear, which we have previously demonstrated (Chapter 11).
Whole-body protein breakdown was calculated using the 
expression; Protein breakdown umol of leucine /kg/h = F 
(umol/kg/h)/ E j^j q  x  100%, where F is the rate of leucine 
infusion and E^^c fs the enrichment of the keto acid (191).
Values were expressed as means ± SD. Statistical analysis 
used Wilcoxon's ranking test for the non parametric, unpaired
'
VI
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data (Mann-Whitney test). Differences were considered 
significant at P values of <0.05.
5,12.4 RESULTS
All patients showed villous atrophy on histological 
examination of their jejunal and duodenal mucosal biopsies 
and they were all negative for Giardia. The disaccharidase 
activities were reduced in all patients (Table 5.12,2).
A plateau level of 5 ± 0.27 APE of tracer enrichments 
was achieved within one h of infusion for both IV and IG 
routes and remained so throughout the infusion period until 
biopsies were obtained at endoscopy (Figure 5.12.1).
:3
»Distal duodenal mucosal protein synthesis rate was markedly 
elevated in coeliac patients compared with control subjects 
whether determined by incorporation of the IV or IG infused 
tracers. IV tracer, coeliac vs. control 3.58 ± 0.45 vs. 2.26 
± 0.22 %/h P<0.05; IG tracer 6.25 ± 0.52 vs. 2.34 ± 0.52 %/h, 
P<0.01 (Figure 5.12.2). Labelling of mucosal intracellular 
amino acids was higher when tracer was given IG than IV but 
there were no differences between the control subjects and 
coeliac patients (Figure 5.12.3), suggesting that the higher 
rate of protein synthesis measured with IG tracer in the 
coeliac patients was not the result of differential precursor 
labelling or luminal tracer malabsorption.
;
:
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from the coeliac patients studied.
Patient Lactase Sucrase Maltase
*
1
s
i
4
:aî
Normal
range
1-12 3-15 10-55
1 0 . 1 0 . 5 2
2 1. 6 4 . 9 1. 9
3 0 . 2 0.3 2
4 0.1 0 . 2 1
5 0 . 2 0.9 5
6 0.0 1 4
7 0 . 0 0 . 4 2
8 0,3 2.9 1. 0
The disaccharidase activities are expressed as international 
unit/gm of wet weight (lU/gm).
i
'■4
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i:
!
S
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Protein/DNA ratios were reduced in the patients with 
coeliac disease compared to the control subjects, 9.2 ± 1.6 
mg/ug vs. 13.0 ± 2.2 mg/ug, respectively P < 0,05 (Figure
5.12.4). The protein synthetic capacity, RNA/protein ratio, 
was elevated in the coeliac patients compared to the control 
subjects, 172 ± 7.5 ug/mg vs. 137.1 ± 5.7 ug/rag
respectively, P < 0.005 (Figure 5.12.5).
Whole-body protein breakdown in coeliac disease was 206 ± 
16 umol leucine/kg/h and in the control subjects 196 ± 44
umol leucin^^g/h, the difference between the 2 groups not 
being statistically significant, suggesting that the effect 
of coeliac disease is localized to the intestinal mucosa.
The keto acid/amino acid ratios after IG delivery of 
tracer amino acids were significantly lower in coeliac 
patients for both tracers; KIC/leucine and KlV/valine were 
0.95 ± 0.03 and 0.94 ± 0.03 in controls and 0.74 ± 0.02 and 
0.79 ± 0.06 in coeliac patients respectively P < 0.05 (Figure 
5.12.6).
Duodenal mucosal tissue in coeliac patient showed a high 
concentration of RNA relative either to DNA or to protein, 
indicative of a substantial capacity for protein synthesis. 
The rates of protein synthesis in terms of RNA were 0.33 for 
the IV route and 0.58 mg protein.h“^.mg RNA"1 (Table 5.12.3).
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Figure 5.12.1 Plasma labelling of valine and leucine tracers 
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Figure 5.12.2 The rates of intestinal mucosal protein 
synthesis in controls and coeliac patients.
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Figure 5.12.3 Intestinal mucosal free tracer enrichment 
during intragastric delivery of tracers in controls and 
coeliac patients.
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Figure 5.12.4 Duodenal mucosal cellular size in controls and 
coeliac patients.
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Figure 5.12.5 Protein synthetic capacity in controls and 
coeliac patients.
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Figure 5.12.6 Keto acid / amino acid labelling ratios after 
intragastric delivery of tracer amino acids in controls and 
coeliac patients.
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TABLE 5.12.3_____Mucosal tissue composition and protein
synthetic capacity in coeliac patients.
I
Protein DNA RNA Prot. synt. capacity
mg.g-1 mg.g“^ mg.g"! mg prot.h“^.mg RNA“*^ Ï
12.67 ± 0.15 0.85 ± 0.06 1.35 ± 0.06 0.33 + 0.05 IV
0.58 ± 0.06 IG
5.12.5 DISCUSSION
This study presents for the first time the effect of 
untreated coeliac disease on the rate of small bowel mucosal 
protein synthesis in vivo. The rate of protein synthesis by 
the small intestinal mucosal cells was higher in coeliac 
patients in spite of the smaller size of the enterocytes. The 
increased rate of mucosal protein synthesis in coeliac 
patients is in agreement with the results of an in vitro 
study by Jones et al.(209). They cultured jejunal mucosa 
from patients with coeliac disease, treated coeliac disease 
and controls with l^^C-labelled leucine for 24 h and found
that protein synthesis by mucosa from untreated coeliac 
patients was significantly greater than by control mucosa.
We calculated the mucosal protein synthesis as fractional 
rate relative to the intracellular tracer enrichment. Ideally 
the precursor should be the aminoacyl tRNA which is difficult
V.to measure (178,179). Therefore, we used free mucosal
§
"V:
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intracellular tracer enrichment as a surrogate for tRNA 
(Chapter 10).
Presentation of the tracer amino acid to the apical 
(luminal) side of the enterocytes seems to be associated with 
higher protein synthetic rate than on presentation of these 
tracers on the basolateral (intravascular) side. This finding 
was unexpected and is not seen in normal healthy subjects, 
probably due to the preferential channelling of amino acids 
from the luminal side because of the immaturity of the 
enterocytes in coeliac disease.
Coeliac disease is caused by damage to the villous 
epithelium of the small intestinal mucosa, giving a 
characteristic histological appearance (210) in response to 
the ingestion of dietary gluten which is present in most 
cereal grains (211). The condition may be accompanied by 
malabsorption of many nutrients, but the clinical picture 
only appears when the small intestinal damage is severe or 
deficiencies appear (12). There is evidence of increased 
mucosal cell turnover with marked proliferation of normal 
crypt cells (212), and our findings are in agreement with 
this. So far the metabolic capacity of these cells remains 
unclear.
Our diagnostic criteria for the diagnosis of coeliac 
disease depended on jejunal biopsy rather than endoscopic 
distal duodenal biopsy. Endoscopic biopsies tend to be 
smaller in size, difficult to orientate and interpret 
(210,213,214,215). They are also of lower disaccharidase 
activities comparing to the jejunal biopsies, particularly so
il
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for the lactase enzyme (216,217). The values of these 
disaccharidase activities are shown in table (5.12.4) (218).
■I
TABLE 5.12.4 Normal values of disaccharidase activities in 
the duodenal and neiunal mucosa.______________________ _________
,
Site Lactase Sucrase Maltase
Duodenum 0.5-7.4 1.3-10.7 5.8-35
Jejunum________1-12____________3-15_____________ 10-55____
The KIC/Leu and KlV/Val ratios were below 1 and were II
significantly lower in coeliac patients suggesting more 
dilution of the keto acids resulting from elevated rate of 
protein breakdown and turnover. The intestinal mucosa showed
'evidence of atrophy as manifested by the decreased
protein/DNA ratio. The extrapolation that the protein/DNA 
ratio reflects epithelial cellular size has been confirmed by 
conducting histomorphoraetric studies on the small intestinal 
mucosal biopsies from the coeliac patients and the control 
subjects (Chapter 13). The capacity of protein synthesis
?
(RNA/protein) is elevated in the coeliac patients. This is 
probably a reflection of the immaturity of the enterocytes 
lining the villus and/or elevated rate of mucosal protein
.breakdown. In conclusion the small intestinal mucosal cells 
in coeliac disease seem to be immature, hence there is poor 
development of absorptive and metabolic functions.
The results of this study provides further insight into 
the changes in protein metabolism at tissue level which occur
,ï
i
127
in patients with coeliac disease. The tissue biopsies in 
these studies are made up, not only of intestinal epithelial 
cells but also comprise many other cell types e.g mesenchymal 
cells, immunocytes and fibrous tissue. The contribution of 
the lamina propria to the protein synthesis is negligible, as 
the rate of mucosal protein synthesis was the same in all the 
untreated coeliac patients in spite of the varying degree of 
inflammatory cellular infiltration in those patients. 
Furthermore, it has been found by analytical subcellular 
fractionation that most of the net protein synthesis takes 
place in the enterocytes and only negligible amounts 
synthesised by the cells of the lamina propria (141) Further 
developments of the current technique of measuring mucosal 
protein synthesis in vivo is required to allow the 
contribution of each cell type to the rate of protein 
synthesis in the whole biopsy to be determined,
Jones et al. found that protein synthesis by treated non- 
responsive coeliac mucosa was significantly less than 
untreated coeliac mucosa but greater than control mucosa 
(209). Further in vivo study is required to reevaluate the 
rate of protein synthesis in patients with coeliac disease 
who have responded clinically and histologically to a gluten 
free diet as well as in those patients who have not responded 
to this diet.
5.13.6 SUMMARY
We have applied a robust, reproducible method for the 
measurement of protein synthesis in the gastrointestinal
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mucosa to investigate possible differences between the rate 
of duodenal mucosal protein synthesis in coeliac patients and 
normal control subjects. Eight patients, means ± SD (51 ± 10 
y, 57 ± 11 kg, 160 ± 6 cm) with newly-diagnosed untreated
coeliac disease and seven control subjects (48 ± 11 y, 71.5 ± 
12 kg, 172 ± 10 cm) received primed, continuous IG and IV 
infusions of L-[1-^^C]leucine and L-[l-^^C]valine after an 
overnight fast. Distal duodenal biopsies were obtained at 
endoscopy performed after 240 min of infusion. Protein 
synthesis was calculated from protein labelling relative to 
intracellular free amino acid enrichment, after appropriate 
mass spectrometric measurements. Rates of duodenal protein 
synthesis were significantly greater in coeliac patients than 
in control subjects (IV tracer, coeliac vs. control, 3.58 ± 
0.45 vs. 2.26 ± 0.22 %h”l, P < 0.05; IG tracer, 6.25 ± 0.97 
vs. 2.34 ± 0.52 %h~l respectively, P < 0.01). The rates of 
mucosal protein synthesis calculated on the basis of the 
tracer infused via the IG route were higher in patients with 
coeliac disease than in control subjects. Tissue protein/DNA 
ratios were significantly reduced in coeliac patients 
(coeliac vs. control, 9.2 ± 1.6 mg/ug vs. 13.0 ± 2.2 mg/ug 
respectively, P < 0.05) suggesting smaller mucosal cell size 
in coeliac patients. Despite the villous atrophy and reduced 
cell size observed in coeliac disease, the rates of mucosal 
protein synthesis are markedly elevated. These results 
suggest that a high rate of protein synthesis may be adaptive 
to a high rate of protein breakdown or mucosal cell loss in 
coeliac patients.
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CHAPTER 13
CRYPT CELL HISTQMORPHOMETRY IN COELIAC DISEASE: COMPARISON
5.13.1 INTRODUCTION
Coeliac disease is characterized by malabsorption and
■#
______________________________________________________________________WITH MUCOSAL PROTEIN AND DNA COMPOSITION AND CORRELATION TO
VITAMIN B12 AND FOLATE STATUS
#I
typical but non-specific histological changes in the small 
intestinal mucosa in response to ingestion of dietary gluten. 
The etiology of coeliac disease remains unresolved but it 
seems that genetic and immunologic factors play an important 
role in the pathogenesis of this disease (211).
The lesions are always most sever"in the upper part of the 
small intestine and become progressively less marked distally 
(212). The pathological changes are characterized by sub-
I
total villous atrophy, abnormal surface mucosal cells, 
increased cellularity of the lamina propria; mainly 
lymphocytes and plasma cells, and elongation of the crypts of 
Lieberkuhn (205,207). Under light microscopy the crypts cell 
damage is recognized by reduction in cell height, often 
associated with increased cytoplasmic basophilia, vacuoiation 
and nuclear irregularity with loss of polarity. There is 
pronounced mitotic activity with a substantially increased 
mitotic index (212,219).
The most important diagnostic feature of coeliac disease 
is that a measurable improvement in villous architecture
-I
'Vi"iC
disease, is associated with folate deficiency (224). Both
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takes place when gluten is withdrawn from the diet (211) . 
Direct visual observation of histological sections under 
light microscopy lacks discrimination compared to historaetry
:(220). Therefore a more sensitive measure of the 
architectural changes in coeliac disease would be invaluable
to follow up response to treatment.
The small intestinal mucosa is a tissue with the most 
rapid turnover of any in the body (205) and as such it 
resembles the haemopoetic system. There is an analogy between 
the intestinal mucosa and the haemopoetic system and a 
nomenclature was proposed (221) based on haematological 
principles. The crypt cells in the germinative zone can be 
called "enteroblast" and the adult absorptive cells, which 
show no mitosis and have limited life span resembling 
peripheral blood cells, then be termed "enterocytes". The S
whole process of cell turnover can be termed "enteropoeiesis" 
(222).
Lack of adequate levels of vitamin B^2 folate is the 
cause of megaloblastic anaemia secondary to vitamin
I
Ideficiency (223). Structural or functional damage in the 
upper third of the small intestine, such as in coeliac
vitamin B^2 and folic acid are required for synthesis of
I
thymidylate and therefore, of DNA (224). Morphological
changes in the "enterocytes" similar to those seen in the 
erythrocytes would be expected in response to vitamin 
deficiency.
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5.13.2 AIMS
The aims of this study were; 1) to asses the nuclear, 
cellular and cytoplasmic surface area of crypt cells in the 
small intestinal mucosa in coeliac disease patients and 
controls; 2) to compare these characteristics with the 
protein and DNA composition of the enterocytes; 3) to asses 
the effect of gluten withdrawal from the diet on the 
histomorphometric characteristics of crypt cells in the 
small intestinal mucosa in coeliac disease patients; and 4) 
to correlate these histomorphometric measurements to the 6^2 
and folate status and mean corpuscular volume (MCV) in the 
control subjects and patients studied.
5.13.3 PATIENTS AND METHODS
Small intestinal mucosal samples were obtained from 40 
subjects, 21 untreated coeliac disease, means ± SD (42 ± 14 
y , 66.5 ± 12 kg, 169 ± 11 cm, male/female 10/9) and 19
controls (48 ± 10 y , 61 ± 11 kg, 161 ± 6.5 cm, male/female
10/11) .
DNA and protein composition of the intestinal mucosa were 
determined in 7 control subjects (Table 4.10.1) and 8 coeliac 
patients (Table 5.12.1) as previously described (Chapter 12).
Small intestinal biopsies from the jejunum were taken by 
Crosby Kugler capsule and from the distal duodenum via the 
endoscope and immediately fixed in Buin's solution (saturated 
aqueous picric acid 75 ml, 40% formaldehyde 25 ml and glacial 
acetic acid 5 ml) (225) after mounting them on filter paper,
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villous side upwards. The biopsies were carefully oriented 
and embedded in paraffin wax and sections (4u) were cut on 
the same microtome and the speed of cutting kept steady. 
These sections were stained with haematoxylin and eosin 
according to standard procedures (226) for routine 
histopathological examination. All sections were viewed with 
a Leitz microscope type 307-148.001 (Leitz-Wetzler, Germany) 
through a X500 objective; appropriate photomicrographs were 
taken with an Orthomat camera (Leitz-Wetzler, Germany) and 
recorded on Kodak Tec-Pan 35 mm film. With this level of 
magnification, which was used throughout, a measurement of 
1mm on the microphotograph was equivalent to 4.4 u on the 
section.
The nuclear and cellular surface area were measured in 50 
crypt cells in each section. The cytoplasmic surface area was 
obtained by subtracting the nuclear surface area from the 
cellular surface area.
In the sections studied the nuclear shape was elliptical 
therefore the surface area was calculated from the 
expression;
A =TT ab = 3.14159 ab = 3.142 ab, 
where A is the area, a the long radius and b the short 
radius (227).
The surface area of the crypt cells was measured by the
tracing method (220). The crypt cells were grouped into
sectors of 5 adjacent cells and drawings were made on
acetate sheets and the shapes cut out neatly with scissors
and weighed. On the same acetate sheet ten 10 x 10 mm squares
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expression;
Sector's surface area = Sector's Weight x 1936/176
Comparison of the cellular, cytoplasmic and nuclear surface 
area as well as protein/DNA, cytoplasmic/nuclear surface area 
ratios and serum folate levels between control and coeliac
as■ÿ
were drawn, cut out and weighed using a sensitive weighing 
balance (Unimatic single pan weighing balance, Stanton 
Instruments Ltd, London). The weight of these squares was 176 
± 4 ug and the surface area 1936 (10 mm x 10 mm = 44 u x
44 Li = 1936). The crypt cell's sectors were weighed using the 
same balance and the surface area was calculated from the
i■■■:■and divided by 5 to obtain the cellular surface area. aJ..The measurement of nuclear surface area of the crypt cell was repeated in 6 patients 12-18 months after the introduction of 
gluten free diet to assess the effect of gluten withdrawal on 
the historaorphometry.
Blood samples were obtained at the time of biopsy from 12 
normal subjects (age 38 ± 14 y, weight 62,5 ± 10.5 kg, height
166.5 ± 10 cm and male/female ratio 4/8) and 13 coeliac
disease patients (age 45.5 ± 10 y, weight 62 ± 10 kg, height
162 ± 7 cm and male/female ratio 6/7) and sent for analysis. ■
Vitamin B^g/ serum folate and red blood cell (RBC) folate
were measured by a radioassay method (Becton Dickinson 
SimulTRAC Radioassay kit. New York 10962-1294) (228,229) and
the MCV was measured according to the standard procedure 
using automated counter in the Haematology laboratory.
Results are expressed as ranges and/or means ± SD.
i
■■
disease was achieved by using the non-parametric paired test
a;
aI
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(Mann-Whitney U test) . The changes pre and post therapy were 
carried out using paired Student t test. Correlation of the 
nuclear surface area to the 5^2/ serum folate, RBC folate and 
MCV was carried out using the non-parametric Spearman's rank 
correlation test and the Two-tailed t test for P values. 
Difference between values were considered to be statistically 
significant at a P value of < 0.05.
0.84 u^/u^, P < 0.008) suggesting that mucosal cell size is
■f
!
s■ ÛX
5.13.4 RESULTS
The nuclear surface area in the coeliac disease 
patients was higher than in the control subjects (coeliac 
disease vs. controls; 125.52 ± 21.78 vs. 44.47 ± 10.75 ,
P < 0.008). There was no significant difference in the
cellular surface area between the two groups (coeliac disease 
vs. controls ; 602.06 ± 101.09 vs. 556.65 ± 12.52 ,
P=NS) (Figure 5.13.1).
Protein/DNA ratio was reduced in the coeliac disease 
patients compared with the controls (coeliac disease vs. 
controls; 9.2 ± 1.6 mg/ug vs. 13.0 ± 2.2 mg/ug respectively,
P < 0.05) (Figure 5.12.4). The cytoplasmic surface
area/nuclear surface area ratio was again reduced in the 
coeliac disease patients compared with the controls (coeliac 
disease patients vs. controls; 3.67 ± 0.58 u^/u^ vs. 9.11 ±
reduced in coeliac disease patients (Figure 5.13.2).
Table 5.13.1 shows the levels of vitamin 8^2, serum 
folate and RBC folate as well as the MCV. Serum folate level
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was low in coeliac disease (coeliac disease patients vs 
controls; 2.92 ± 0.83 vs. 5.48 ± 2.1 ng/ral, P <0.03).
TABLE 5.13.1 Vitamin B12, serum folate and RBC folate levels
and MCV values of coeliac oatients and controls.
NORMAL COELIAC CONTROL
VITAMIN B^2 150-730 119-693 217-625
(pg/ml) 440 376 .38 404.82
± 290 ± 181.97 ± 135.35
SERUM FOLATE 2.2-11.4 1.8-3.7 2.2-9.9
(ng/ral) 6 . 8 2 . 92* 5 .48
± 4.6 ± 0.83 ± 2.1
RBC FOLATE 106-614 6 9—426 120-583
(ng/ral) 360 224.64 368.42
± 254 ± 117.13 ± 145.3
MCV 76-96 76.8-96.8 81.2-94.
(fl) 86 88.48 89.28
± 10 ± 5.78 ± 3.85
Coeliac disease vs. control; P < 0.03 
levels are expressed as ranges and means ± SD
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Figure 5.13.1 Nuclear surface area and cellular surface area 
of the crypt cells in coeliac patients and control subjects.
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Figure 5.13.2 Cytoplasmic surface area/nuclear surface area 
ratio of the crypt cells in coeliac patients and normal 
controls.
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The correlation between nuclear surface area and vitamin 
B^2/ serum folate, RBC folate and MCV in coeliac disease 
patients and controls are shown in figures 5.13.3, 5.13.4,
5.13.5 and 5.13.6 respectively. The serum folate levels in 
coeliac disease showed a significant negative correlation 
with the nuclear surface area (y=6.08-0.03x, r2=0.62, P<0.02)
The introduction of gluten free diet resulted in clinical 
response in the patients who were compliant with the 
treatment. However, the histological response as assessed by 
routine light microscopy was variable. The nuclear surface 
area of the crypt cells showed a reduction from 125.97 ±
12.34 u2 down to 72.05 ± 4 u^, p < 0.001 (Figure 5.13.7).
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Figure 5.13.3 Correlation between the serum vitamin B^2 level 
and crypt cell nuclear surface area in control subjects and 
coeliac patients.
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Figure 5.13.5 Correlation between the red blood cell folate 
level and crypt cell nuclear surface area in control subjects 
and coeliac patients.
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Figure 5.13.7 The effect of gluten-free diet on the nuclear 
surface area of the crypt cell in patients with coeliac 
disease.
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suitable for certain histological investigations. It offers
mitotic index (212,231).
The DNA in the nucleus is packaged into 46 chromosomes in
cells that have a diploid set of chromosomes (36).This study
5.13.5 DISCUSSION
Histometry, the measurement of tissue, is particularly
objectivity and makes statistical analysis easier as direct 
visual observation lacks discrimination and is inconsistent 
compared to histometry. It also facilitates the comparison of 
histological studies from different centres (220).
Intestinal biopsy is of central importance in the 
investigation of coeliac disease. Most studies concentrated 
on the histological abnormality of the villous architecture 
in the form of villous atrophy associated with crypts 
hyperplasia and increased prominence of the intraepithélial 
lymphocytes and other leukocytes (230). Information on the
«
histomorphometric characteristics of the crypts cells in 
coeliac disease is lacking apart from the mention of high
the nucleated diploid human cells and it is the same for all
showed significant increase in the nuclear surface area in 
the coeliac disease patients which is probably a reflection 
of increased mitotic activity and so the chromosomes are not 
densely packaged as in the resting cells.
The change in the nuclear surface area of the crypt cell 
following the introduction of gluten free diet provides an 
early indicator of the response to this therapy in coeliac 
disease.
s
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The reduced cytoplasmic surface area and protein content 
of the small intestinal mucosal cells is an indication of the 
immaturity of the mucosal cells in coeliac disease and could
.be more sensitive than direct light microscopy.
In our control group the levels of vitamin EU?, serum
folate and RBC folate were within the normal ranges therèform ,-y
--no significant correlation with the MCV.
In coeliac disease the pathological changes tend to 
affect the proximal part of the small intestinal mucosa more 
than the distal part and the terminal ileum, and as such the 
absorptive capacity of the proximal part of the small
intestine is affected to a greater extent. As the folate and
coeliac disease is common and may result in changes in the
•1
iron are absorbed from the proximal part of the small
intestine and vitamin B.g is absorbed from the terminal
-V'.ileum, therefore in coeliac disease there is deficiency of
folate and iron rather than vitamin B^  g unless the disease is12
S O  sever and extensive to involve the terminal ileum. About 
one third of coeliac disease patients have a low cobalamine 
level (232). In our coeliac disease patients the cobalamine 
levels were lower than the controls, but the difference was 
not significant (Table 5.13.1). Because of the combination of 
iron and folate deficiencies the MCV values in the coeliac 
disease patients were within the normal range as a result of 
the dimorphic picture. Furthermore, splenic atrophy in
Iblood film like target cells, Howel-Jolly bodies, RBC 
fragments and erythroblasts which affect the MCV (232). It 
seems that the nuclear surface area of the crypt cell in
i
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coeliac disease is affected by the folate status and not the 
ferrous status.
Further studies are needed to measure the small 
intestinal mucosal tissue folate and iron levels and 
correlate these levels directly with the histomorphometric 
characteristics of the crypt cells in coeliac patients.
5.13.6 SUMMARY
We performed histomorphometry on the crypt cells of small 
intestinal mucosal samples obtained from patients with 
untreated coeliac disease and normal subjects. The 
histomorphometric characteristics were; compared with the 
protein and DNA composition of the intestinal mucosa; 
correlated to the vitamin B^2 ^^‘3. folate status; and repeated 
after the introduction of gluten free diet. Jejunal and 
distal duodenal biopsy specimens were obtained from 40 
subjects (19 controls and 21 patients with untreated coeliac 
disease) and analysed morphometrically by light microscopy 
using the tracing method. DNA and protein composition of the 
intestinal mucosa were assessed in a group of 7 controls and 
8 coeliac disease, and vitamin B 2^ serum folate as well
as red cell folate were measured in the remaining subjects 
(13 coeliac disease and 12 controls), Histomorphometry was 
repeated in 6 patier]^t^^ith coeliac disease after the \ 
introduction of gluten free diet. The nuclear surface area 
in coeliac disease was significantly greater than in the 
controls (coeliac disease vs, controls, means ± SD, 125.52 ± 
21.78 lï2 v s . 44.47 ± 10.75 u'^ , P < 0.008). There was no
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significant difference in the cellular surface area between 
the two groups. Protein/DNA ratio and cytoplasmic/nuclear 
surface area ratio were both reduced in patients with coeliac 
disease compared to controls (9.2 ± 1.6 mg/ug vs. 13.0 ± 2.2 
mg/ug, P < 0.05; 3.67 ± 0.58 vs. 9.11 ± 0.84 ,
P<0.008 respectively). Serum folate was low in coeliac 
disease patients (coeliac disease vs. controls 2.92 ± 0.83 
vs. 5.48 ± 2.1, P < 0.03) and showed significant negative 
correlation with the nuclear surface area (y=6.08-0.03x, 
r2=o.62, P < 0.02). No significant correlation was found
between the nuclear surface area and vitamin 8^2, serum 
folate and red blood cell folate in the normal subjects nor 
there was significant correlation between nuclear surface
,area in the coeliac disease patients and vitamin 6^2 and red 
cell folate. Nuclear surface area was reduced after the 
introduction of gluten free diet (pre-treatment vs, post­
treatment; 125.97 ± 12.34 u^ vs. 72.05 ± 4 u^, p < 0.001). 
These results suggest that the nuclear surface area in 
coeliac disease is greater than normal, probably a
reflection of increased mitotic activity. Serum folate was 
low in coeliac disease and correlated negatively well with
■the nuclear surface area of the crypt cells. The reduction in 
the nuclear surface area after withdrawing gluten from the 
diet can be used as an early indicator of response to this 
therapy.
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process. Studies in rats provide evidence of depressed small
CHAPTER 14
SMALL INTESTINAL MUCOSAL PROTEIN SYNTHESIS IS DEPRESSED IN 
PATIENTS WITH ALCOHOLIC LIVER DISEASE AND CORRELATES WITH 
WHOLE-BODY PROTEIN BREAKDOWN
I6,14.1 INTRODUCTION
Malnutrition is commonly associated with alcoholism 
(233,234), By the time patients have developed liver disease 
which is clinically obvious they often show evidence of 
protein-energy malnutrition (235,236) and other nutritional 
deficiencies (237). There is some difficulty in accurately 
defining the nutritional status in chronic alcoholism (238). 
Among the methods used are measurement of nitrogen status and 
metabolism by such indices as the ratio of concentrations of 
branched-chain to aromatic amino acids in plasma and the rate 
of plasma amino acid turnover obtained using labelled leucine 
(233) . There is evidence of wasting of lean body mass in
:
alcoholic liver disease, especially of skeletal muscle, but 
little is known of the involvement of the gut in the wasting I 
:intestinal mucosal protein synthesis (239) and intestinal 
protein synthesis (240,241) in response to alcohol suggesting 
the existence of similar deficits in man. Furthermore, little 
is known about the functional correlates of possible 
gastrointestinal involvement in man in response to chronic 
ethanol ingestion.
■ )
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6.14.2 AIMS
The aims of this study were; 1) to measure indices of 
mucosal cell size and protein synthetic capacity and the rate 
of small intestinal mucosal protein synthesis, 2) to 
investigate links between protein turnover in the gut and 
those in the whole-body in patients with alcoholic liver 
disease and in normal healthy subjects, and 3) to correlate 
the small intestinal mucosal protein synthetic rates and 
whole-body protein turnover rates with the severity of 
alcoholic liver disease and the amounts of alcohol consumed.
6.14.3 PATIENTS AND METHODS
Eight patients with alcoholic liver disease were studied 
at the Department of Gastroenterology, Glasgow Royal 
Infirmary (Table 6.14.1). Each subject gave written consent 
after a full explanation of the nature of the study. Approval 
was obtained from the Ethics Committee of Glasgow Royal 
Infirmary University NHS trust.
The results from these patients with alcoholic liver 
disease were compared with the results obtained from a group 
of eight normal healthy subjects who had been consuming less 
than 10 units of alcohol a week and had normal liver function 
tests (Table 6.14.2).
All patients had regularly consumed in excess of 50 units
of alcohol weekly until the day of admission to the hospital. 
Reasons for emergency hospital admission were jaundice, 
abdominal pain, ascites, weight loss, exhaustion or vomiting 
(Table 6.14.3). Patients with infection, encephlaopathy,
■ I'•3
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gastrointestinal bleeding, uncorrected coagulation status or 
any previous history of hepatic failure were excluded from 
the study. All patients showed clinical, biochemical and 
ultrasonic evidence of parenchymal liver damage (Table 
6.14.4). Liver biopsy in 2 patients confirmed the diagnosis 
of alcoholic liver disease and in one of them fell just short 
of a diagnosis of hepatic cirrhosis. Screen for autoimmune 
(antismooth muscle antibodies, antimitochondrial antibodies 
and anti nuclear factor) and viral factors (hepatitis A, B 
& C) were negative in all patients. None of the patients was 
taking drugs that could affect the liver, apart from alcohol. 
All patients were started on a daily diet restricting sodium 
(to 40 mmol) and water (to 1 liter) with normal protein 
intake (100 gm) on admission to hospital.
TABLE 6.14.1 Characteristics of patients with alcoholic 
liver disease studied.
■Ï'
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Patient Age-Y Sex Weight-kg Height-cm %Ideal BW
1 45 M 67 172 98.38
2 41 F 63 157 111.70
3 42 M 54 162 85 .31
4 44 M 74 177 104.52
5 45 M 78 164 121.68
6 37 M 98 180 135.36
7 31 M 86 177 121.47
8 45 M 72 175 103.30
«
I
:
I
;S
% ideal BW : % ideal body weight (198)
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They were also started on spironolactone (Aldactone; 
Searle, Bucks, England) 100-200 mg daily to control their 
fluid retention.
TABLE 6.14.2 Characteristics of normal subjects studied for
small intestinal mucosal protein synthesis.
Patient Age-Y Sex Weight-kg Height-cm %Ideal BW
1 57 M 65 158 105.01
2 53 M 85 185 112.58
3 59 M 70 178 98. 18
4 45 M 56 172 82 . 23
5 54 M 87 185 115.23
6 24 F 63 166 102.77
7 21 M 62 162 97.95
8 40 F 79 160 135.97
% ideal BW : % ideal body weight (198)
To gain an insight into the severity of alcoholic liver 
disease in the patients studied I used a biochemical scoring 
system which involves measuring AST, ALT, serum bilirubin, 
serum albumin, gamma GT and vitamin 8^2 level (Table 6.14.5). 
I used this scoring system to correlate the severity of 
alcoholic liver disease with the small intestinal mucosal 
protein synthetic rates and whole-body protein turnover 
rates. It has been found that alcoholic liver disease is 
characterised by distinct patterns of AST and ALT elevations 
(243,244), and that the serum vitamin B^g concentration is a
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useful marker for the severity of necrosis observed in liver 
biopsy (245). Therefor I have included these indices in the 
scoring system.
TABLE 6.14.3 Alcohol consumption and reasons for hospital 
admission of patients with alcoholic liver disease.
Patient Alcohol Consumption Reason for Admission
Amount* Duration'*' to Hospital
60
56
55
60
50
60
80
75
15
18
25
10
15
16
30
Jaundice & abdominal 
pain
Ascites, peripheral 
odema & exhaustion. 
Ascites, Jaundice & 
weight loss 
Ascites & Jaundice 
Abdominal pain 
Abdominal pain 
Jaundice & withdrawal 
fits
Jaundice, vomiting, 
weight loss & ascites
Amount : 
^Duration
units per week 
: in years
One unit of alcohol 10 gm of ethanol, 
30 ml of whisky, 
100 ml of wine or 
250 ml beer (242)
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TABLE 6.14.4 Biochemical and clinical characteristics of 
patients with alcoholic liver disease.
Pt. AST ALT Bill GGT Alb Vit B^2 Ascites’^ Hepar*
1 410 69 190 1070 32 1027 4- + 2
2 38 31 48 380 34 540 + + + 4
3 158 80 15 2010 47 885 H--I- + 1
4 94 28 818 335 34 738 +  4" + 3
5 129 216 8 250 32 325 4- 3
6 58 25 53 53 39 554 4- 2
7 75 61 79 740 36 539 4- 2
8 106 20 170 61 33 540 4-4-4- 4
* Hepatomegaly measured in cm below the costal margin
+ Degrees of ascites, + mild, ++ moderate and 4-4-4- severe
Normal Ranges:
AST 12-48 U/1
ALT 3-55 U/1
Serum bilirubin 3-22 umol/1 
Serum albumin 35-55 g/1 
GGT
Vitamin 8^2
<36 U/1
150-730 pg/1
!•
1?
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TABLE 6.14.5 Scoring system for the severity of alcoholic 
liver disease.
PARAMETER SCORE
0 1 2 3
AST normal <2-fold >2”fold >3-fold
ALT normal <2-fold >2-fold >3-fold
Bilirubin <35 >35 >70 >150
Albumin >35 <35 <30 <25
GGT normal <2”fold >2-fold >3-fold
Vitamin B^ g^ <average >average >normal >2-fold
Ii
I
§
:: ,;;4
-1I
0-6 mild 
6-12 moderate 
12-18 severe
L-[i-13c]leucine 99 Atom % was dissolved in sterile, non- 
pyrogenic 0,9% NaCl solution (150 mmol/liter) immediately 
before administration and infused IV through a 0.20 u filter.
The subjects were studied in the morning after an 
overnight fast, A priming dose of L-[ ] pe^^eine Img/kg
body weight was given IV over one min; a constant infusion of 
the same tracer at a rate of Img /kg body weight/h using 120 
ml of 0.9% NaCl was then continued for 4 h. After 240 min 
of continuous infusion upper gastrointestinal endoscopy was 
performed and multiple distal duodenal biopsies were
;I
II:
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obtained. The range of the pooled wet weight of biopsies was 
56.1-88.0 mg. Further biopsies were taken for histology.
in this study
Venous blood samples were taken at -15, 0, 60, 120, 180 and
240 min respectively. Venous blood samples were centrifuged 
and separated plasma kept in liquid nitrogen until analysis 
Figure 3.9.3 illustrates the experimental protocol followed
I
The labelling and concentrations of plasma phenylalanine.
leucine and KIC were measured by standard GCMS techniques 
using t-BDMS derivatives (199). Mucosal tissue samples were
frozen in liquid nitrogen immediately on sampling, and 
samples pooled for storage at -70^0. The pooled mucosal 
tissue samples were analysed for concentration of protein,
RNA, and DNA (190) . The labelling with of leucine in
hydrolysed protein was measured by using preparative GC to 
isolate the amino acid with IRMS of the CO2 liberated by 
ninhydrin (185). Plasma protein from the pre-infusion samples 
was used to estimate basal body protein labelling for use
in the calculation of mucosal protein synthetic rate.
Protein synthesis was calculated as a fractional rate and 
whole-body protein breakdown was calculated from plasma 
KIC as described previously (Chapter 9).
■ ;Values were expressed as means ± SD and mean (range) . 
Statistical analysis used the non parametric, unpaired 
Student t-test, Spearman's rank correlation test or the two- 
tailed t test as appropriate. Differences were considered 
significant at P values of <0.05.
■■Ï
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6.14.4 RESULTS
A plateau level of 5.1 ± 0.75 APE of L-[i-13c]peucine
enrichments was achieved within one h of infusion and 
remained so throughout the infusion period until biopsies 
were obtained at endoscopy.
Distal duodenal mucosal protein synthesis rate was found 
to be lower in the alcoholic liver disease patients than in 
the control subjects (alcoholic liver disease vs. control;
2.04 ± 0.18 vs. 2.58 ± 0.32 %/h, P < 0.003) (Figure 6.14.1),
The protein/DNA ratio, an index of cell size, was also 
lower in the patients with alcoholic liver disease than in 
the control subjects (9.23 ± 0.91 mg/ug vs. 13.0 ± 2.2 mg/ug 
respectively, P <0.002) (Figure 6.14.2). The RNA/protein 
ratio, an index of the protein synthetic capacity of the 
tissue, was higher in the alcoholic liver disease patients 
than in the control subjects (160.29 ± 14.01 ug/mg vs. 137.1 
± 5.7 ug/mg respectively, P < 0.003) (Figure 6.14.3).
Values of whole-body protein breakdown in alcoholic liver 
disease and control subjects were similar (204 ± 18 and 195 ± 
44 umol leucine/kg/h respectively, P=NS).
Mean leucine (BCAA) concentration was significantly low
in alcoholic liver disease (alcoholic liver disease vs. 
control; 95.99 ± 15.72 umol/1 vs. 132.31 umol/1, P < 0.001) 
and mean phenylalanine (aromatic amino acid) concentration
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Figure 6.14.1 Rates of small intestinal mucosal protein
synthesis in patients with alcoholic liver disease and
controls.
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Figure 6.14.2 Protein/DNA ratios in patients with alcoholic
liver disease and controls.
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Figure 6.14.3 Protein synthetic capacities in patients with
alcoholic liver disease and controls.
161
was significantly high in alcoholic liver disease (alcoholic 
liver disease vs. control; 71.02 ± 6.82 vs. 55.62 ± 4.82
umol/1, P <  0.001) (Figure 6.14.4).
The severity of alcoholic liver disease in the patients 
studied was moderate, average (range), 8.4 (5-13) of a scale
0-18 (Figure 6.14.5) . ViI
it:
The severity of alcoholic liver disease correlated 
positively well with the whole-body protein turnover 
(y=119.2+9.7x, r=0.88, P < 0.01) and negatively with the
rates of small intestinal mucosal protein synthesis rate
'(y=2.67-0.07x, r=0.72, P < 0.05) (Figure 6.14.6). No
correlation was found with the reported amount of alcohol 
consumed over the years by the patients studied (Figure
6.14.7).
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ALD vs. controls, P < 0.001 for both amino acids
Figure 6.14.4 Blood concentrations of leucine and
phenylalanine in patients with alcoholic liver disease and
controls.
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Figure 6.14.5 The severity of alcoholic liver disease in the 
patients studied.
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y = 2 .67-0.07X, 
r=0.72, P<0.05
y=119.2+9.7x, 
r=0.88, P<0.01
300
o 200 -
100
10 12 14
4 6 8 10
Severity of ALD
Figure 6.14.6 The correlation between the severity of 
alcoholic liver disease and the rates of small intestinal 
mucosal protein synthesis and whole-body protein turnover.
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r=Q.31, P=NS
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Figure 6.14.7 The correlation between the amount of alcohol 
consumed and the rates of small intestinal mucosal protein 
synthesis and whole-body protein turnover.
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6.14.5 DISCUSSION
The results of this study showed that small intestinal 
mucosal protein synthesis was depressed by 21% and this 
depression is accompanied by a 16% increase in the protein
synthetic capacity of the intestinal mucosa and an overall 
stability of the whole-body protein turnover.
Previous work in liver cirrhosis showed a fall in protein 
synthesis of other tissues, e.g skeletal muscle, accompanied 
by an overall fall in whole-body protein turnover (246). In 
another report the whole-body protein turnover was found to 
be higher than normal control (247). The change in whole-body 
protein turnover probably depends on the severity of the 
liver disease (248). Although in this study there has been no 
real difference in the whole-body protein turnover between I
r;:i;
alcoholic liver disease and the controls, but there was a 
significant, positive correlation between the indices of 
disease severity and the whole-body protein turnover rate. 
The rise in the severity of alcoholic liver disease also 
closely correlated with the reduction in the rate of small 
intestinal protein synthesis (Figure 6.14.6).
The reduced protein/DNA ratio in alcoholic liver disease 
suggests a smaller size of the mucosal cells or simply a 
reduced protein content of the intestinal mucosal tissue as 
part of the general reduction in the total lean body mass. 
Patients with significant alcoholic liver disease tend to 
have a lower protein intake than usual (249) and this poor 
dietary intake is probably responsible for the alteration in
16,
lean body mass and fat stores found in alcoholic liver 
disease patients (245).
The protein synthetic capacity is elevated in alcoholic
■ÎÆliver disease which could be a response to the catabolic 
effect of alcohol or to meet the elevated protein 
requirements in liver disease (247).
Alcohol can induce defects in the intestinal transport of 
various amino acids in rat, such as phenylalanine, leucine, 
glycine, alanine, methionine and valine (250,251). These 
defects might affect the concentration of various amino acids 
beside the effect of the altered liver metabolism and 
handling of these amino acids in particular the aromatic 
amino acids. Plasma clearance does not seem to be a factor in 
the changes seen in the concentrations of some amino acids 
such as leucine in alcoholic liver disease (252). The amino 
acids concentrations in our patients are in keeping with
previous reports (252,253,254).
Previous work in our department suggested that in
alcoholic patients there is functional impairment of water 
and electrolytes absorption without associated changes in the 
small intestinal mucosal histology (255). Animal work 
suggested a direct damaging effect of alcohol on the
intestinal mucosa causing atrophy or shortening of the 
intestinal villi (256). In our study no abnormality was 
detected in the small intestinal mucosal histology.
Furthermore, we have found that mucosal villous atrophy is 
associated with elevated rather than reduced rates of mucosal 
protein synthesis (Chapter 12).
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In conclusion, it remains to be established whether the 
reduced rate of small intestinal mucosal protein synthesis 
found in alcoholic liver disease is related to poor dietary 
intake, direct alcohol effect or due to the alcoholic liver 
disease. Further studies are required to measure small 
intestinal mucosal protein turnover in alcoholic liver 
disease after abstinence.
6.14.6 SUMMARY
We have applied a method using stable isotope labelled 
amino acids to measure small intestinal mucosal protein 
synthesis to investigate the effect of alcoholic liver
disease on the function of the small intestine; we have also 
measured whole-body protein turnover. Sixteen subjects were 
studied, 8 normal volunteers (means ± SD) (44 ± 15 y , 71 + 12 
kg, 171 ± 11 cm) and 8 patients with alcoholic liver disease 
(43 ± 7 y, 74 ± 14 kg, 171 ± 8 cm) , All subjects received
primed, continuous IV infusions of L-[l-^^C]leucine, 1 mg/kg
body weight/h after an overnight fast. After 4 h of tracer 
infusion, distal duodenal biopsies were obtained via 
endoscopy. Protein synthesis was calculated from protein 
labelling relative to intracellular leucine enrichment, after 
appropriate mass spectrometric measurements, Whole-body 
turnover was calculated from plasma xiC enrichments.
Rates of duodenal mucosal protein synthesis were 2.58 ± 0.32 
(%h-l, mean ± SD) in the normal subjects vs. 2.04 ± 0.18 in 
the alcoholic liver disease patients, P < 0.003 despite the 
fact that protein synthetic capacity (ug RNA/mg protein) was
;
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higher in alcoholic liver disease (alcoholic liver disease 
vs. control; 160.29 ± 14.01 vs. 137.1 ± 5.7 ug/mg, P <
0.003); the mucosal cell size, as indicated by the Iprotein/DNA ratio, was lower in alcoholic liver disease (alcoholic liver disease vs. control; 9.23 ± 0.91 vs. 13 ±
2.2 mg/ug; P < 0.002). Although the mean rates of whole-body 
protein turnover were not different between the two groups 
(alcoholic liver disease vs. control; 201 ± 27 vs. 196 ± 44 
umol leucine/kg/h; P=NS) in the alcoholic liver disease 
patients there was an inverse relationship between rate of 
intestinal mucosal protein synthesis and extent of severity 
of alcoholic liver disease (r = 0.72, P < 0.05) and a direct 
relationship between rate of whole-body protein turnover and 
severity of alcoholic liver disease (r = 0.88, P < 0.01) and 
a negative correlation with small intestinal mucosal protein
I
'■8
synthesis (r = 0.72, P < 0.01). Thus there was an inverse 
relationship between rate of small intestinal mucosal protein
synthesis and rate of whole-body protein turnover in 
alcoholic liver disease patients which was not seen in the 
normal control subjects. The rate of intestinal mucosal 
protein synthesis was depressed by 21% in alcoholic liver 
disease despite a 16% increase in the protein synthetic 
capacity. The lean tissue wasting observed in alcoholic liver 
disease appears to extend to the gastrointestinal tract, 
which shows a depressed anabolic activity (despite a 
sufficient synthetic capacity) in proportion to whole-body 
breakdown. The functional significance of these changes 
remains to be established.
:i,
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CHAPTER 15
REGIONAL VARIATION IN THE RATES OF SMALL INTESTINAL MUCOSAL 
PROTEIN SYNTHESIS IN SUBJECTS WITH ILEOSTOMY
7.15.1 INTRODUCTION
The small intestine extends from the pylorus to the
ileocaecal valve and measures about 5 ra (3.5-6.5 m) in
length. It is divided into 3 regions; the duodenum is the
first 25 cm y the jejunum is the proximal 40% and the ileum 
is the distal 60% of the remaining small bowel. There is no 
recognized line of division between the jejunum and the 
ileum. There are anatomical, structural, histological and 
functional differences between these three regions of the
small intestine (206,257).
In the intestinal mucosa, cell function is different at 
different levels; the physiology of absorption is not the 
same in the jejunum and ileum (9), the rates of cell renewal 
are different, and it is likely that rates of protein 
turnover are also different (37), Recently there has been a 
considerable interest in human gastrointestinal protein 
metabolism (39,192) and work in animal preparations 
suggested that the small intestine contributes significantly 
to the whole-body protein turnover in spite of /it's
;
relatively small contribution to whole-body protein mass
(193) . No data are available on the comparability of the
,rates of mucosal protein synthesis between the various
regions of the small intestine.
:s
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We have developed a safe, reproducible and reliable 
method to measure protein synthesis in the gastrointestinal 
mucosa using BCAAs labelled with (Chapter 10) and used
it to address this question.
7.15.2 AIMS
The main aims of this study were; 1) to measure the rate 
of mucosal protein synthesis in the jejunum and ileum of 
ileostomy subjects, 2) to investigate possible differences 
between the rates of protein synthesis in these regions of 
the small intestine, and 3) to assess the effect of
ileostomy on the whole-body protein turnover.
7.15.3 PATIENTS AND METHODS
Six subjects with ileostomy, three men and three women 
age 27-71 years, weight 54-84 kg were studied (Table
7-15.1). Each subject gave written consent after a full 
explanation of the nature of the study. Approval for the 
studies was obtained from the local Ethics Committee of
Glasgow Royal Infirmary University NHS Trust.
Patients with ileostomy were recruited to allow access to 
the terminal ileum. Five of them had undergone total
colectomy for ulcerative colitis and one patient had colonic 
inertia and still has her colon in situ though she did have 
an ileostomy.
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studied for small intestinal mucosal orotein svnthesis.
Patient Age-Y Sex Weight-kg Height-cra %Ideal BW
68
72
35
70
31
27
F
M
M
M
F
F
65
84
51
83
54
64
159
170
165
172
172
177
113.04 
125.19 
78.95 
121.88 
83 . 72 
9 5 .24
% ideal BW : % ideal foody weight (198)
Results obtained from a group of 8 normal volunteer 
subjects (mean ± SD) (44 ± 15 y , 71 ± 12 kg, 171 ± 11 cm)
were used as controls (Table 6.14.2).
L-[1-^^C]leucine 99 Atom % was dissolved in sterile, non- 
pyrogenic 0.9% NaCl solution (150 mmol/liter) immediately 
before administration and was sterilized by passage through 
a 0.2 0 micron filter.
The subjects were studied in the morning after an 
overnight fast. Venous blood samples were taken, centrifuged 
and separated, plasma was kept in liquid nitrogen. A 
priming dose of L-[1~^^C]leucine Img/kg body weight was 
given IV over one rain. A constant infusion of the same 
tracer at a rate of Img /kg body weight/h using 120 ml of 
0.9% NaCl was then continued for 4 h. The same rate of
174
infusion was used in both groups and was kept constant
during the time of infusion. After 4 h of continuous 
infusion small intestinal mucosal samples were obtained from 
the jejunum and the ileum. The jejunal biopsies were
obtained using a Crosby Kugler capsule (113) which was 
introduced 2 h after the start of the tracer infusion. The 
position of the capsule was about 10 cm distal to the 
ligament of Trietz and was verified radiologically. The 
range of pooled wet weight of jejunal biopsies was 11.1-22.1 
mg. Immediately after taking the jejunal biopsy, ileoscopy 
was performed and multiple ileal biopsies obtained for ^^C 
analysis and histology. The range of pooled wet weight of 
ileal biopsies was 60,0-79.8 mg. Venous blood samples were 
taken at -15, 0, 60, 120, 180 and 240 min respectively and
separated plasma kept in liquid nitrogen with the biopsies.
The labelling of plasma leucine and KIC was measured by 
means of standard GCMS techniques using t-BDMS derivatives 
(199). Mucosal tissue samples were frozen in liquid nitrogen 
immediately on sampling, and samples pooled for storage at 
-70^C. Plasma protein from the pre-infusion samples was used 
to estimate basal body protein ^^C labelling for use in the
calculation of mucosal protein synthetic rate. The labelling
with C of leucine in hydrolysed protein using preparative 
gas chromatography and isotope ratio mass spectrometry of 
the CO2 liberated by ninhydrin (185).
The rates of small intestinal mucosal protein synthesis 
and whole-body protein breakdown were calculated as
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previously described (Chapter 9). Values were expressed as 
means ± SD, Statistical analysis used Student t-test for the 
non parametric, unpaired data. Differences were considered 
significant at P values of < 0.05.
7.15.4 RESULTS
The plasma leucine enrichment reached a plateau of 7.12
± 0.57 APE in the ileostoraates and 5.11 ± 0.56 APE in the
control subjects; ileostomates vs. control, P < 0.005,
within one h of IV L~[1-^^C]leucine infusion and remained so 
throughout the infusion period until biopsies were obtained 
(Figure 7.15.1). The KIC enrichment was also higher in the 
ileostomy patients than in the controls, ileostomates vs. 
controls; 5.32 ± 0.59 vs. 3.82 ± 0.53, P < 0.005 (Figure
7.15.2). There was no difference in the KIC/leucine ratio 
between the two groups, controls vs. ileostomates; 0.76 ± 
0.07 vs. 0.75 ± 0.04, P = NS.
The rates of jejunal and ileal mucosal protein synthesis 
were 2.14 ± 0.20 and 1.20 ± 0.20 %h“  ^ respectively,
P <  0.001 (Figure 7.15.3).
The rate of whole-body protein turnover was lower in the 
ileostomates, ileostomates vs. controls; 145 ± 15 vs. 196 ± 
44 umol/kg/h, P < 0.01 (Figure 7.15.4).
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Figure 7.15.1 Plasma leucine enrichment in the control 
subjects and ileostomy patients.
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Figure 7.15.2 Plasma alpha-ketoisocaproate enrichment in the 
control subjects and ileostomy patients.
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Figure 7.15.3 Jejunal and ileal mucosal synthetic rates in 
the ileostomy subjects
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7.15.5 DISCUSSION
The results of this study show that the fractional rate 
of protein synthesis in the various regions of the small 
intestine is not the same in ileostomates. The rate of 
protein synthesis in the jejunal mucosa is substantially 
higher than the rate in the ileal mucosa. The results 
strongly suggest that the rate of protein synthesis in the 
ileal mucosa is half that in the duodenal mucosa of normal 
subjects (Chapter 10), and about 25 times greater than the 
rate of protein synthesis observed in skeletal muscles I
(175,204).
The ileal mucosal biopsies from the patient who had 
ileostomy showed normal mucosal pattern on histological 
examination and the pathological reports on the surgical 
specimens of the resected colons as well as the case records 
of those patients were reviewed and the diagnosis of 
ulcerative colitis was verified. The patient with colonic
inertia had a normal colonoscopy and upper gastrointestinal 
endoscopy with normal histology of the mucosal biopsies. In 
this subject the ileoscopic biopsies were taken from various 
areas and sent for histology and from about 10 cm and 60 cm 
away from the stoma for protein synthesis measurement. The
rate of protein synthesis in the distal ileal mucosa was
_ 1 - 11.05 %h and in the proximal ileal mucosa 1.22 %h which
further confirmed the fact that the distal part of the small
I
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intestinal mucosa has a lower rate of protein synthesis than 
the proximal part.
All subject studied were within normal nutritional status
and had not made any major modifications to their diet as a
result of the ileostomies. On one occasion a subject did not 
tolerate the Crosby Kugler capsule and on another occasion 
the capsule failed to fire, hence we only had 4 jejunal
S'
mucosal samples and 6 ileal mucosal samples.
Ileostomy appears to be associated with a reduction in 
the whole-body protein turnover and increased values for the 
tracer amino acid and ketoacids plasma enrichments despite 
using the same rate of tracer infusion which was kept
constant in both groups. The explanation of this is not 
fully understood, whether it is related to reduced lean 
tissue mass following colectomy, leucine corapartmental 
changes or changes in the efflux of leucine and KIC from 
various organs in the body, remains to be established. 
However, this observation does indicate that the colon 
contributes significantly to the whole-body protein 
turnover.
There were attempts to avoid permanent ileostomy and 
establish a normal route of evacuation by ileo-rectal 
anastomosis (258) and more recently, over the past 15 years 
or so, by the reservoir operation to create a pelvic pouch 
and maintain the voluntary control over evacuation 
(259.260). There has been reports on the morphological, 
histochemical and functional changes in the ileal mucosa
J-
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following such operations (261,262,263). Pouchitis; varying 
degrees of villous atrophy with inflammation has become the 
most important long term complication affecting pelvic ileal 
pouches (262). The physiological mechanisms underlying pouch 
adaptation and inflammation are poorly understood. The 
method we used to measure the rate of protein, synthesis in 
the ileal mucosa has a potential role in the investigation 
of these patho-physiological changes.
Further studies are required to measure the duodenal 
mucosal protein synthesis in ileostomates and compare this 
with the results of the duodenal mucosa obtained from normal 
volunteers.
7,15.6 SUMMARY
We have applied a robust and reproducible method to 
measure protein synthesis in the gastrointestinal mucosa to 
investigate possible differences in the rates of mucosal 
protein synthesis between the proximal and distal regions of 
the small intestine in ileostomates and to assess the effect 
of ileostomy on protein turnover. Six subjects with 
ileostomy were studied (mean ± SD) (46 ± 21 y, 6 5 ± 14 kg,
169 ± 6 cm) . Results from a group of 8 normal volunteer
subjects (44 ± 15 y , 71 ± 12 kg, 171 ± 11 cm) were used for
comparison. The presence of ileostomy in these subjects 
allowed practical access to the distal region of the small 
intestine. The terminal ileum was histologically normal in 
all ileostomy subjects studied. All subjects received
Î
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primed, continuous IV infusions of L-[l- C]leucine after an 
overnight fast. After 4 h of tracer infusion jejunal 
biopsies were obtained using Crosby Kugler capsule and ileal 
biopsies were obtained via endoscopy at the same time.
Protein synthesis was calculated from protein labelling 
relative to intracellular leucine enrichment, after 
appropriate MS measurements. The results are presented as 
means + SD. Rates of jejunal and ileal mucosal protein 
synthesis were 2,14 ± 0.2 and 1.2 ± 0.2 (%h-^) respectively; 
jejunal vs. ileal P < 0.001. Plasma leucine enrichment was, 
ileostomates vs. controls; 7.12 ± 0.57 vs 5.11 ± 0.55 APE,
P < 0.005 and plasma KIC enrichment was, ileostomates vs. 
controls; 5.32 ± 0.59 vs. 3.82 ± 0.53 APE, P < 0.005. The 
whole-body protein turnover rate was, ileostomates vs. 
controls; 145 ± 15 vs. 196 ± 44 umol/kg/h, P < 0.01, In the 
small intestinal mucosa of subjects with ileostomy the rates 
of protein synthesis were different at different levels, 
being significantly higher at the proximal level and lower 
at the distal level. The plasma leucine enrichment increased 
by 28% and plasma KIC enrichment increased by 26% with a 
significantly reduced whole-body protein turnover. These 
changes are probably related to the reduction in the size of 
the plasma amino acid compartment or reduced lean tissue 
mass following colectomy and indicate that the colon has a 
significant contribution to the whole-body protein turnover.
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DISCUSSION
The fractional rates of protein synthesis observed in the 
normal duodenal mucosa were high at 2.5 %h"l, being some 25- 
50 times greater than those previously observed for skeletal 
muscle (175,204) and also about two to three times greater
than those determined for normal colonic mucosa (39,173,194). 
Despite the substantial differences in the extent of 
labelling of the intracellular and plasma pool of leucine and 
valine when the tracers were administered IG or IV, and 
despite the substantial differences in the absolute extent of 
labelling of mucosal protein, the rate of mucosal protein 
synthesis calculated on the basis of the intracellular amino 
acid pool labelling were identical.
The results suggest that in the post-absorptive state, 
there is no detectable preferential channelling of amino
■■acids into protein synthesis from the apical or basolateral 
membrane of the small intestinal mucosal cells. The lower 
plateau values for plasma labelling for the tracers infused 
via the IG route than the IV route suggested that the IG 
tracers were being diluted to a greater extent by amino acids
released from protein breakdown, most likely in the gsplanchnic tissue. The results suggest that there is little 
transamination of the BCAAs during their passage from the 
gastrointestinal lumen into the peripheral blood in 
accordance with the known low capacities of the gut and liver 
for BCAA transamination (203).
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It is impossible to exactly quantify the total amount of 
small intestinal mucosal protein in order to calculate the 
absolute amount of protein synthesis contributed by the
gastrointestinal tract but the high rate suggests that 
mucosal protein synthesis is a major contributor to whole 
body protein turnover.
Leucine tracer was incorporated into gastrointestinal
protein to an extent proportional to the time of exposure of 
the tissue to the tracer at least when delivered IV. We have 
assumed that this is also the case for the tracers delivered 
IG. Therefore the calculated in this infusion protocol is 
equal to the FSR when using the expression Kg (%h"l) = (E^ - 
Eg/Ep) X 1/t X 100.
The effect of untreated coeliac disease on the rate of
small intestinal mucosal protein synthesis in vivo was 
determined in this work. The rate of protein synthesis by the 
small intestinal mucosal cells was higher in coeliac patients 
in spite of the smaller size of the enterocytes. The
increased rate of mucosal protein synthesis in coeliac
'patients is in agreement with the results of an in vitro 
study by Jones et al. (209). Presentation of the tracer amino 
acid to the apical (luminal) side of the enterocytes seems to
be associated with higher protein synthetic rate than on
presentation of these tracers on the basolateral
(intravascular) side. This finding was unexpected and is not 
seen in normal healthy subjects, probably due to the
preferential channelling of amino acids from the luminal side ÎË;iî:a
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because of the immaturity of the enterocytes in coeliac 
disease. In coeliac disease there is evidence of increased
this. The KIC/Leu and KlV/Val ratios were significantly low
1
i
mucosal cell turnover with marked proliferation of normal 
crypt cells (212), and our findings are in agreement with
in coeliac patients suggesting more dilution of the keto 
acids resulting from elevated rate of protein breakdown and 
turnover. The intestinal mucosa showed evidence of atrophy as
■manifested by the decreased protein/DNA ratio. The capacity
of protein synthesis (RNA/protein) is elevated in the coeliac 
patients. This is probably a reflection of the immaturity of 
the enterocytes lining the villus and/or elevated rate of
mucosal protein breakdown. The contribution of the lamina 
propria to the protein synthesis of the mucosa is negligible 
and most of the protein synthesis takes place in the
enterocytes and only negligible amounts synthesised by the 
cells of the lamina propria (141).
Intestinal biopsy is of central importance in the
■iinvestigation of coeliac disease. Information on thehistomorphometric characteristics of the crypts cells in 
coeliac disease is lacking apart from the mention of high 
mitotic index (212,231). This study showed significant 
increase in the nuclear surface area in the coeliac disease 
patients which is probably a reflection of increased mitotic 
activity. The change in the nuclear surface area of the
I
crypt cell following the introduction of gluten free diet 
provides an early indicator of the response to this therapy 
in coeliac disease. We found a significant reduction in the
f
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surface area of the crypt cell's nuclei in patients who
shortening of the intestinal villi (256). In our study no
showed clinical as well as histological response to gluten
free diet. The results of the histomorphometric study
suggests that the nuclear surface area of the crypt cell in
coeliac disease is affected by the folate status and not the
.ferrous status.
The results of the study in alcoholic liver disease showed 
that the rate of small intestinal mucosal protein synthesis 
was depressed by 21%, despite a 16% increase in protein 
synthetic capacity. There was an overall stability of the 
whole-body protein turnover. The change in whole-body protein 
turnover probably depends on the severity of the liver 
disease (248). I have found a significant, positive 
correlation between the indices of disease severity and the 
whole-body protein turnover rate. The rise in the severity of 
alcoholic liver disease also closely correlated with the 
reduction in the rate of small intestinal protein synthesis.
The reduced protein/DNA ratio in alcoholic liver disease 
suggests a smaller size of the mucosal cells or simply a 
reduced protein content of the intestinal mucosal tissue as 
part of the general reduction in the total lean body mass.
-,The protein synthetic capacity is elevated in alcoholic liver 
disease which could be a response to the catabolic effect of 
alcohol or to meet the elevated protein requirements in liver 
disease (247). Animal work suggested a direct damaging effect
of alcohol on the intestinal mucosa causing atrophy or
:ÿï'
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abnormality was detected in small bowel mucosal histology. It 
remains to be established whether the reduced rate of small 
intestinal mucosal protein synthesis found in alcoholic liver 
disease is related to poor dietary intake, direct alcohol 
effect or due to the alcoholic liver disease.
The fractional rate of protein synthesis in the various 
regions of the small intestine is not the same in 
ileostomates. The rate of protein synthesis in the jejunal 
mucosa is substantially higher than the rate in the ileal 
mucosa. The results strongly suggest that the rate of protein 
synthesis in the ileal mucosa is half that in the duodenal 
mucosa of normal subjects, and about 25 times greater than 
the rate of protein synthesis observed in skeletal muscles
(175,204). Ileostomy appears to be associated with a 
reduction in the whole-body protein turnover and increased 
values for the tracer amino acid and ketoacids plasma 
enrichments despite using the same rate of tracer infusion 
which was kept constant in both groups. The explanation of 
this is not fully understood, whether it is related to 
reduced lean tissue mass following colectomy, leucine 
compartmental changes or changes in the efflux of leucine and 
KIC from various organs in the body, remains to be 
established.
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CONSIDERATIONS ON FUTURE APPLICATIONS OF STABLE ISOTOPES AND 
MUCOSAL PROTEIN SYNTHESIS TECHNIQUE
determined.
Further developments of the current technique of measuring 
mucosal protein synthesis in vivo can be expected to allow
i
Î
The present method for the measurement of protein
synthesis has applications in various tissues and organs in
the body, as long as these tissues and organs are capable of
being biopsied or approached peroperatively.
Of particular interest is to study the physiological 
response of the gastrointestinal mucosa to nutrient supply 
either enterally or parenterally. The response of whole-body 
protein dynamics to food depends on the previous dietary
history especially the amount of protein in the diet (264). 
In skeletal muscle, the response to food is similar in
direction, but probably greater in extent, than that in the 
whole-body; that is, protein synthesis increases and protein 
breakdown falls during feeding (265,266,267). The effect of 
feeding on intestinal protein synthesis is not known and the 
reports available on this subjects are inconclusive 
(268,269). Therefore this method could be used to measure the 
effect of feeding, both enteral and parenteral, on small
intestinal protein synthesis. This is an important aspect 
which has implications for the preservation of the function
of the gastrointestinal tract during enteral and parenteral 
feeding. The extent to which human mucosal protein synthesis 
can be modulated by physiological influences including
nervous, hormonal and nutritional effects, remains to be
fS'
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Another application is to reevaluate the rate of protein 
synthesis in patients with coeliac disease who have responded
the contribution of each cell type to the rate of protein 
synthesis in the whole biopsy to be determined.
clinically and histologically to a gluten free diet as well 
as in those patients who have not responded to this diet. It
has been found that the rates of in vitro protein synthesis 
by treated non-responsive coeliac mucosa significantly lower 
than the rates in the untreated coeliac mucosa but greater
than the rates in the control mucosa (209).
Further application of the method described here is to 
study the small intestinal protein turnover in alcoholic 
liver disease after abstinence to see if this has any effect 
on the intestinal protein metabolism.
Pouchitis is the most important long term complication 
affecting pelvic ileal pouches (262), and the physiological 
mechanisms underlying pouch adaptation and inflammation are
poorly understood. The method we used to measure the rate of 
protein synthesis in the ileal mucosa has a potential role in 
the investigation of these patho-physiological changes.
iTo evaluate the effect of ileostomy on the rate of small 
intestinal protein synthesis further study is required to 
measure the duodenal mucosal protein synthesis and to compare 
it with the results of the duodenal mucosa obtained from 
normal volunteers.
Various other gastrointestinal diseases can be studied on 
the same line such as Crohn's disease using the method 
described in this thesis to evaluate the rates of mucosal
'
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protein synthesis before and after certain treatment 
modalities such as steroids and elemental diet.
The latest development of very accurate mass 
spectrometers in recent years have extended the range of work 
which is possible with stable isotopes. Because of this 
accuracy and the safety of using stable isotopes comparing 
with radioactive isotopes, we have developed a new method for 
the measurement of gastrointestinal mucosal protein synthesis 
which can be added to the armament of research and 
investigative ■ gastroenterology. Various applications of 
stable isotopes have already been mentioned (Chapter 4), in 
addition some other applications merit a particular 
attention.
The use of tracer amino acids to measure the absorptive 
capacity of the small intestine and the rate of absorption in 
normal subjects and in patients with malabsorption such as 
short bowel syndrome. Such test would be minimally invasive 
technique and it has at>^ 's applications in clinical practice / 
to evaluate protein absorption in various disease entities. 
The technique of stable isotope labelling also has a 
potential wide range of applications in the study of 
absorption of various nutrients, trace elements and drugs and 
to evaluate the influence of various factors on their 
absorption. In generalized malabsorption there is almost 
always impaired fat absorption, and the most reliable test is 
the quantitative faecal fat analysis (206), such as dual 
isotope fat absorption (DIFA) test (270,271), This test 
employs radioactive isotopes which could be replaced by
194
stable isotopes. The classic test for malabsorption commonly 
used in clinical practice to assess the absorptive capacity 
of the small intestine is the D-xylose absorption test (272), 
This test is flawed with problems and potential uncertainty 
regarding the accuracy of itu^^ results (11,273,274), 
therefore there is a need for more sensitive and specific 
absorptive tests.
Another application is to use ^^C-acetate breath test to 
monitor gastric emptying rate in patients with 
gastrointestinal motility disorders and to follow up the 
effect of treatment in these patients. There have been 
attempts to use ^^C-glycine and ^“^C-octanoic acids to measure 
gastric emptying (100,101,102). This test is safer than the 
radioscintigraphy, which is the current method used in 
clinical practice, thereby reducing radiation exposure to the 
patient. It is also a valid, non-invasive technique. In 
addition breath tests are easy to perform, even for the 
elderly or disabled patients and can be carried out at the 
bedside or even outside the hospital. Breath samples can be 
analysed after completion of the sampling at a convenient 
time and can easily be repeated to monitor response to 
therapy. It is very cost effective method in this time when 
cost is an important issue.
In conclusion, the development and current applications 
of stable isotope technology has provided much valuable and 
practical information which will in time help to develop more 
effective and practical techniques in clinical investigation 
and research.
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CONCLUSIONS
The principle aims of the thesis have been achieved.
A new, robust, safe, reproducible and reliable method for 
the measurement of gastrointestinal mucosal protein synthesis 
has been developed. This method employs the use of amino acid 
tracer incorporation principle for the measurement of protein 
synthesis. The delivery of tracer amino acid was by following 
the primed-constant infusion rather than the flooding dose 
technique.
In normal subjects there was no preferential channelling 
of the tracer amino acid when it was delivered via the IV or 
the IG route. The incorporation of tracer amino acid in the
gut mucosal protein was linear with the exposure time.
In untreated coeliac disease patients the rates of
duodenal mucosal protein synthesis were elevated for both IV 
and IG routes. In this group of patients I found that the IG 
route was associated with higher rates of gut mucosal protein 
synthesis than the IV route, for reasons remain to be
established. This variation was not found in normal subjects. 
There was evidence of reduced mucosal cell size and increased 
protein synthetic capacity in coeliac patients. The mucosal 
cellular atrophy was confirmed by the histomorphometric study 
which also showed evidence of increased crypt cell nuclear 
surface area associated with reduced serum folate levels.
I
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In the alcoholic liver disease patients the rate of small
I (intestinal protein synthesis was depressed despite the —  -1
 ^ increase in the protein synthetic capacity of the intestinal 
\ mucosa\ The whole-body protein turnover rates were the same 
in the alcoholic liver disease patients and the control 
subjects. However, there was a positive correlation with the 
indices of disease severity which correlated inversely with
a
Ï
the rates of mucosal protein synthesis.
In the ileostomy subjects there was a regional variation 
in the rates of small intestinal mucosal protein synthesis, 
being higher proximally and lower distally. The rates of 
whole-body protein turnover were lower in the ileostomates 
and the enrichment of the tracer amino acid reached higher 
levels. II
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